View Filing Data

Print Document View Excel Document

Summary Of Significant Accounting Policies - Additional Information (Details)	12 Months Ended
	Dec. 31, 2019 USD ($) segment	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)
Summary Of Significant Accounting Policies [Line Items]
Restricted cash	$ 15,000,000.0	$ 51,500,000
Other-than-temporary impairment losses	0	0	$ 0
Depreciation expense	$ 156,700,000	105,900,000	$ 82,100,000
Number of operating segments \| segment	1
Performance obligation period	The Company’s system sale arrangements generally include a five-year period of service. The first year of service is generally free and included in the system sale arrangement, and the remaining four years are generally included at a stated service price.
System sales arrangement, warranty period	1 year
Capitalized contract costs	$ 51,500,000	$ 34,200,000
Market-based implied volatility (period)	1 year
Market-based implied volatility (percent)	100.00%
Cash flow hedges de-designated (period)	2 months
Likelihood of tax benefits being realized upon ultimate settlement	50.00%
Long-lived assets, percent	85.00%	88.00%
Minimum
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life, intangible asset	1 year
Sales-type leases term	24 months
Maximum
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life, intangible asset	9 years
Sales-type leases term	84 months
Derivative, term of contract	12 months
Maximum \| Internal use software
Summary Of Significant Accounting Policies [Line Items]
Useful Lives	5 years
Accounts Receivable \| U.S.
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage	66.00%	71.00%
Total Revenue \| U.S.
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage	70.00%	71.00%	73.00%
Total Revenue \| Outside of U.S. (“OUS”)
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage	30.00%	29.00%	27.00%

Description of the Business	12 Months Ended
Description of the Business	Dec. 31, 2019
Accounting Policies [Abstract]
Description of the Business	DESCRIPTION OF THE BUSINESSIntuitive Surgical, Inc. (“Intuitive” or the “Company”) develops, manufactures, and markets the da Vinci^® Surgical System and the Ion^TM endoluminal system. The Company’s products and related services enable physicians and healthcare providers to improve the quality of and access to minimally invasive care. The systems consist of a surgeon console or consoles, a patient-side cart, a high-performance vision system, and proprietary instruments and accessories.

Consolidated Statements Of Income - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Revenue:
Total revenue	$ 4,478.5	$ 3,724.2	$ 3,138.2
Cost of revenue:
Total cost of revenue	1,368.3	1,120.1	936.2
Gross profit	3,110.2	2,604.1	2,202.0
Operating expenses:
Selling, general and administrative	1,178.4	986.6	810.5
Research and development	557.3	418.1	328.6
Total operating expenses	1,735.7	1,404.7	1,139.1
Income from operations	1,374.5	1,199.4	1,062.9
Interest and other income, net	127.7	80.1	41.9
Income before taxes	1,502.2	1,279.5	1,104.8
Income tax expense	120.4	154.5	433.9
Net income	1,381.8	1,125.0	670.9
Less: net income (loss) attributable to noncontrolling interest in joint venture	2.5	(2.9)	(0.4)
Net income attributable to Intuitive Surgical, Inc.	$ 1,379.3	$ 1,127.9	$ 670.9
Net income per share attributable to Intuitive Surgical, Inc.:
Basic (usd per share)	$ 11.95	$ 9.92	$ 6.01
Diluted (usd per share)	$ 11.54	$ 9.49	$ 5.77
Shares used in computing net income per share attributable to Intuitive Surgical, Inc.:
Basic (shares)	115.4	113.7	111.7
Diluted (shares)	119.5	118.8	116.3
Total comprehensive income attributable to Intuitive Surgical, Inc.	$ 1,405.0	$ 1,130.1	$ 664.3
Joint venture
Operating expenses:
Less: net income (loss) attributable to noncontrolling interest in joint venture	2.5	(2.9)	0.0
Product
Revenue:
Total revenue	3,754.3	3,089.1	2,565.3
Cost of revenue:
Total cost of revenue	1,119.1	906.2	756.3
Service
Revenue:
Total revenue	724.2	635.1	572.9
Cost of revenue:
Total cost of revenue	$ 249.2	$ 213.9	$ 179.9

Revenue - Summary of Contract Assets and Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Revenue from Contract with Customer [Abstract]
Contract assets	$ 20.8	$ 12.4
Deferred revenue	$ 365.2	$ 327.3

Share-Based Compensation - Summary Of Stock Option Activity Under All Stock Plans (Details) shares in Millions	12 Months Ended
	Dec. 31, 2019 $ / shares shares
Number Outstanding
Beginning balance (shares) \| shares	6.2
Options granted (shares) \| shares	0.6
Options exercised (shares) \| shares	(1.3)
Options forfeited/expired (shares) \| shares	(0.1)
Ending balance (shares) \| shares	5.4
Weighted Average Exercise Price Per Share
Beginning balance (usd per share) \| $ / shares	$ 200.79
Options granted (usd per share) \| $ / shares	523.30
Options exercised (usd per share) \| $ / shares	159.46
Options forfeited/expired (usd per share) \| $ / shares	381.82
Ending balance (usd per share) \| $ / shares	$ 246.64

Consolidated Statements Of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Statement of Cash Flows [Abstract]
Net income	$ 1,381.8	$ 1,125.0	$ 670.9
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and loss on disposal of property, plant, and equipment, net	160.0	108.6	86.2
Amortization of intangible assets	43.0	14.2	12.9
Loss (gain) on investment, accretion of discounts, and amortization of premiums on investments, net	(6.0)	1.8	21.2
Deferred income taxes	(8.0)	31.9	60.2
Share-based compensation expense	335.8	261.2	209.1
Amortization of contract acquisition assets	13.1	10.6	10.9
Changes in operating assets and liabilities, net of effects of acquisitions:
Accounts receivable	38.8	(161.3)	(81.4)
Inventory	(360.5)	(279.0)	(115.5)
Prepaids and other assets	(116.9)	(77.7)	(38.9)
Accounts payable	12.3	16.7	14.0
Accrued compensation and employee benefits	57.4	26.2	31.2
Deferred revenue	35.5	54.3	43.7
Other liabilities	11.9	37.1	219.4
Net cash provided by operating activities	1,598.2	1,169.6	1,143.9
Investing activities:
Purchase of investments	(3,346.2)	(2,581.9)	(1,995.0)
Proceeds from sales of investments	107.3	274.0	1,861.3
Proceeds from maturities of investments	2,569.8	1,533.6	703.1
Purchase of property, plant, and equipment and intellectual property	(425.6)	(187.4)	(190.7)
Acquisition of businesses, net of cash	59.7	87.9	0.0
Net cash provided by (used in) investing activities	(1,154.4)	(1,049.6)	378.7
Financing activities:
Proceeds from issuance of common stock relating to employee stock plans	272.8	236.6	415.5
Taxes paid related to net share settlement of equity awards	(159.1)	(120.0)	(56.6)
Repurchase of common stock	(269.5)	0.0	(2,274.0)
Capital contribution from noncontrolling interest	10.0	10.0	2.0
Payment of deferred purchase consideration	(22.6)	(0.3)	0.0
Net cash provided by (used in) financing activities	(168.4)	126.3	(1,913.1)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	(2.2)	(0.1)	2.1
Net increase (decrease) in cash, cash equivalents, and restricted cash	273.2	246.2	(388.4)
Cash, cash equivalents, and restricted cash, beginning of year	909.4	663.2	1,051.6
Cash, cash equivalents, and restricted cash, end of year	$ 1,182.6	$ 909.4	$ 663.2

Goodwill and Intangible Assets - Schedule Of Estimated Future Amortization Expense Of Intangible Assets (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
2019	$ 46.1
2020	18.7
2021	16.0
2022	11.5
2023	9.4
2025 and thereafter	10.4
Net Carrying Amount	$ 112.1	$ 66.7

Income Taxes - Schedule Of Income Before Provision For Income Taxes (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Income before provision for income taxes, U.S.	$ 1,053.7	$ 852.7	$ 774.7
Income before provision for income taxes, Foreign	448.5	426.8	330.1
Income before taxes	$ 1,502.2	$ 1,279.5	$ 1,104.8

Revenue - Revenue Disaggregated by Types and Geography (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Disaggregation of Revenue [Line Items]
Total revenue	$ 1,277.7	$ 1,128.2	$ 1,098.9	$ 973.7	$ 1,046.5	$ 920.9	$ 909.3	$ 847.5	$ 4,478.5	$ 3,724.2	$ 3,138.2
Instruments and accessories
Disaggregation of Revenue [Line Items]
Total revenue									2,408.2	1,962.0	1,636.9
Systems
Disaggregation of Revenue [Line Items]
Total revenue									1,346.1	1,127.1	928.4
Services
Disaggregation of Revenue [Line Items]
Total revenue									724.2	635.1	572.9
U.S.
Disaggregation of Revenue [Line Items]
Total revenue									3,129.5	2,633.5	2,285.8
U.S. \| Instruments and accessories
Disaggregation of Revenue [Line Items]
Total revenue									1,790.4	1,485.2	1,263.1
U.S. \| Systems
Disaggregation of Revenue [Line Items]
Total revenue									830.7	692.2	603.5
U.S. \| Services
Disaggregation of Revenue [Line Items]
Total revenue									508.4	456.1	419.2
Outside of U.S. (“OUS”)
Disaggregation of Revenue [Line Items]
Total revenue									1,349.0	1,090.7	852.4
Outside of U.S. (“OUS”) \| Instruments and accessories
Disaggregation of Revenue [Line Items]
Total revenue									617.8	476.8	373.8
Outside of U.S. (“OUS”) \| Systems
Disaggregation of Revenue [Line Items]
Total revenue									515.4	434.9	324.9
Outside of U.S. (“OUS”) \| Services
Disaggregation of Revenue [Line Items]
Total revenue									$ 215.8	$ 179.0	$ 153.7

Commitments And Contingencies	12 Months Ended
Commitments And Contingencies	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments And Contingencies	COMMITMENTS AND CONTINGENCIES COMMITMENTS Our commitments include an estimated amount of approximately $845 million relating to the Company’s open purchase orders and contractual obligations that occur in the ordinary course of business, including commitments with contract manufacturers and suppliers for which the Company has not received the goods or services, commitments for capital expenditures and construction-related activities for which the Company has not received the services, and acquisition and licensing of intellectual property. Although open purchase orders are considered enforceable and legally binding, the terms generally allow the Company the option to cancel, reschedule, and adjust its requirements based on its business needs prior to the delivery of goods or performance of services. In addition to the above, the Company has committed to make certain future milestone payments to third parties as part of licensing, collaboration, and development arrangements. Payments under these arrangements generally become due and payable only upon the achievement of certain specified developmental, regulatory, and/or commercial milestones. For instances in which the achievement of these milestones is neither probable nor reasonably estimable, such contingencies are not included in the estimated amount. CONTINGENCIES From time to time, the Company is involved in a variety of claims, lawsuits, investigations, and proceedings relating to securities laws, product liability, intellectual property, insurance, contract disputes, employment, and other matters. Certain of these lawsuits and claims are described in further detail below. It is not possible to predict what the outcome of these matters will be, and the Company cannot guarantee that any resolution will be reached on commercially reasonable terms, if at all. A liability and related charge to earnings are recorded in the Consolidated Financial Statements for legal contingencies when the loss is considered probable and the amount can be reasonably estimated. The assessment is re-evaluated each accounting period and is based on all available information, including the impact of negotiations, settlements, rulings, advice of legal counsel, and other information and events pertaining to each case. Nevertheless, it is possible that additional future legal costs (including settlements, judgments, legal fees, and other related defense costs) could have a material adverse effect on the Company’s business, financial position, or future results of operations. During the years ended December 31, 2019, 2018, and 2017, the Company recorded pre-tax litigation charges of $0.5 million, $45.2 million, and $16.3 million, respectively, related to the securities class action lawsuits and the tolled product liability claims described below. A total of $4.2 million and $53.0 million associated with these matters were included in other accrued liabilities in the accompanying Consolidated Balance Sheets as of December 31, 2019, and 2018, respectively. Purported Shareholder Class Action Lawsuits filed April 26, 2013, and May 24, 2013 On April 26, 2013, a purported class action lawsuit entitled Abrams v. Intuitive Surgical, et al., No. 5-13-cv-1920, was filed against a number of the Company’s current and former officers and directors in the U.S. District Court for the Northern District of California. The case has since been retitled In re Intuitive Surgical Securities Litigation, No. 5:13-cv-1920. The plaintiffs sought damages on behalf of a putative class of persons who purchased or otherwise acquired the Company’s common stock between February 6, 2012, and July 18, 2013. The amended complaint alleged that the defendants violated federal securities laws by allegedly making false and misleading statements and omitting certain material facts in certain public statements and in the Company’s filings with the SEC. On June 11, 2018, the Company reached an agreement in principle to enter into a settlement agreement, which stipulates a payment of $42.5 million by the Company. The court granted preliminary approval on October 4, 2018, and on December 20, 2018, the court granted final approval. During the year ended December 31, 2018, the Company recorded a pre-tax charge of $42.5 million for this matter. In connection with the settlement, the Company deposited $42.5 million into an escrow account established for disbursements, which was recorded in prepaids and other current assets in the accompanying Consolidated Balance Sheets as of December 31, 2018. The appeals period expired on January 21, 2019, the payment was made in 2019, and the matter has been concluded. Product Liability Litigation The Company is currently named as a defendant in a number of individual product liability lawsuits filed in various state and federal courts. The plaintiffs generally allege that they or a family member underwent surgical procedures that utilized the da Vinci Surgical System and sustained a variety of personal injuries and, in some cases, death as a result of such surgery. Several of the filed cases have trial dates in the next 12 months. The cases raise a variety of allegations including, to varying degrees, that plaintiffs’ injuries resulted from purported defects in the da Vinci Surgical System and/or failure on the Company’s part to provide adequate training resources to the healthcare professionals who performed plaintiffs’ surgeries. The cases further allege that the Company failed to adequately disclose and/or misrepresented the potential risks and/or benefits of the da Vinci Surgical System. Plaintiffs also assert a variety of causes of action, including, for example, strict liability based on purported design defects, negligence, fraud, breach of express and implied warranties, unjust enrichment, and loss of consortium. Plaintiffs seek recovery for alleged personal injuries and, in many cases, punitive damages. In addition to the filed cases, the Company previously received a substantial number of claims relating to alleged complications from surgeries performed with certain versions of Monopolar Curved Scissor (“MCS”) instruments, which included an MCS tip cover accessory that was the subject of a market withdrawal in 2012 and MCS instruments that were the subject of a recall in 2013. In an effort to avoid the expense and distraction of defending multiple lawsuits, the Company entered into tolling agreements to pause the applicable statutes of limitations for many of these claims and engaged in confidential mediation efforts. As of December 31, 2019, the majority of the “tolled claims” have either been resolved or the matters have been filed. During the years ended December 31, 2019, 2018, and 2017, the Company recorded $0.5 million, $2.7 million, and $16.3 million, respectively, of pre-tax charges to reflect the estimated cost of settling a number of the product liability claims covered by the tolling agreements. As of December 31, 2019, and 2018, a total of $4.2 million and $10.5 million, respectively, were included in other accrued liabilities in the accompanying Consolidated Balance Sheets related to the tolled product liability claims. The Company’s estimate of the anticipated cost of resolving the pending lawsuits and claims is based on negotiations with attorneys for the plaintiffs/claimants. The final outcome of the pending lawsuits and claims, and others that might arise, is dependent on many variables that are difficult to predict and the ultimate cost associated with these product liability lawsuits and claims may be materially different than the amount of the current estimate and accruals and could have a material adverse effect on the Company’s business, financial position, and future results of operations. Although there is a reasonable possibility that a loss in excess of the amount recognized exists, the Company is unable to estimate the possible loss or range of loss in excess of the amount recognized at this time. Patent Litigation On June 30, 2017, Ethicon LLC, Ethicon Endo-Surgery, Inc., and Ethicon US LLC (collectively, “Ethicon”) filed a complaint for patent infringement against the Company in the U.S. District Court for the District of Delaware. The complaint, which was served on the Company on July 12, 2017, alleges that the Company’s EndoWrist Stapler instruments infringe several of Ethicon’s patents. Ethicon asserts infringement of U.S. Patent Nos. 9,585,658, 8,479,969, 9,113,874, 8,998,058, 8,991,677, 9,084,601, and 8,616,431. A claim construction hearing occurred on October 1, 2018, and the court issued a scheduling order on December 28, 2018. On March 20, 2019, the court granted the Company's Motion to Stay pending an Inter Parties Review to be held at the Patent Trademark and Appeals Board to review patentability of six of the seven patents noted above and vacated the trial date. On August 1, 2019, the court granted the parties' joint stipulation to modify the stay in light of Ethicon's U.S. International Trade Commission ("USITC") complaint against Intuitive involving U.S. Patent Nos. 8,479,969 and 9,113,874, discussed below. On August 27, 2018, Ethicon filed a second complaint for patent infringement against the Company in the U.S. District Court for the District of Delaware. The complaint alleges that the Company’s SureForm 60 Staplers infringe five of Ethicon’s patents. Ethicon asserts infringement of the U.S. Patent Nos. 9,884,369, 7,490,749, 8,602,288, 8,602,287, and 9,326,770. The Company filed an answer denying all claims. On March 19, 2019, Ethicon filed a Motion for Leave to File a First Amended Complaint, removing allegations related to U.S. Patent No. 9,326,770 and adding allegations related to U.S. Patent Nos. 9,844,379 and 8,479,969. On July 17, 2019, the court entered an order denying the amendment, without prejudice, and granting the parties' joint stipulation to stay the case in its entirety in light of the USITC investigation involving U.S. Patent Nos. 9,844,369 and 7,490,749, discussed below. On May 30, 2019, Ethicon filed a complaint with the USITC, asserting infringement of U.S. Patent Nos. 9,884,369, 7,490,749, 9,844,379, 9,113,874, and 8,479,969. On June 28, 2019, the USITC voted to institute an investigation (No. 337-TA-1167) with respect to claims in this complaint. The accused products include the Company's EndoWrist 30, EndoWrist 45, SureForm 45, and SureForm 60 Staplers, as well as the stapler reload cartridges. The evidentiary hearing is set for April 20-24, 2020, and the target for completion of the investigation is December 7, 2020. An unfavorable ruling by the USITC could have an adverse effect on our results of operations, including a prohibition on importing the accused products into the U.S. or necessitating workarounds that may limit certain features of our products. Based on currently available information, the Company is unable to make a reasonable estimate of losses or range of losses, if any, arising from these matters. Commercial Litigation On February 27, 2019, Restore Robotics LLC and Restore Robotics Repair LLC ("Restore") filed a Complaint alleging anti-trust claims against the Company. On May 13, 2019, Restore filed an Amended Complaint alleging anti-trust claims relating to the da Vinci Surgical System and EndoWrist service, maintenance, and repair processes. On September 16, 2019, the Court partially granted and partially denied the Company's Motion to Dismiss the Amended Complaint. On September 30, 2019, the Company filed an Answer denying the anti-trust allegations and a Counterclaim against Restore. The Company filed Amended Counterclaims after the Court partially granted and partially denied Restore's Motion to Dismiss the Counterclaim. The Amended Counterclaims allege that Restore violated the Federal Lanham Act, the Federal Computer Fraud and Abuse Act, and Florida's Deceptive and Unfair Trade Practices Act and that Restore is also liable to the Company for Unfair Competition and Tortious Interference with Contract. On January 7, 2020, the Court denied Restore's Motion to Dismiss the Amended Counterclaims. In its initial scheduling order, the Court stated that it anticipate trial in this case to occur on or before February 2022. Based on currently available information, the Company is unable to make a reasonable estimate of loss or range of losses, if any, arising from these matters.

Goodwill and Intangible Assets - Schedule of Summary of Changes in Goodwill (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Goodwill [Roll Forward]
Beginning balance	$ 240.6	$ 201.1
Acquisition activity	65.4	40.2
Translation and other	1.2	(0.7)
Ending balance	$ 307.2	$ 240.6

Net Income Per Share - Computation Of Basic And Diluted Net Income Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Earnings Per Share [Abstract]
Net income attributable to Intuitive Surgical, Inc.	$ 357.7	$ 396.8	$ 318.3	$ 306.5	$ 292.5	$ 292.5	$ 255.3	$ 287.6	$ 1,379.3	$ 1,127.9	$ 670.9
Weighted-average shares outstanding basic (shares)									115.4	113.7	111.7
Add: Dilutive potential shares									4.1	5.1	4.6
Weighted-average shares used in computing diluted net income per share (shares)									119.5	118.8	116.3
Basic net income per share (usd per share)	$ 3.09	$ 3.44	$ 2.76	$ 2.67	$ 2.56	$ 2.57	$ 2.25	$ 2.55	$ 11.95	$ 9.92	$ 6.01
Diluted net income per share (usd per share)	$ 2.99	$ 3.33	$ 2.67	$ 2.56	$ 2.45	$ 2.45	$ 2.15	$ 2.44	$ 11.54	$ 9.49	$ 5.77

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Income Taxes - Schedule Of Deferred Tax Assets (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Deferred tax assets:
Share-based compensation expense	$ 95.6	$ 87.2
Expenses deducted in later years for tax purposes	42.0	29.1
Intangible assets	362.3	351.9
Research and other credits	56.1	40.1
Other	10.4	9.0
Gross deferred tax assets	566.4	517.3
Valuation allowance	(57.2)	(42.3)
Deferred tax assets	509.2	475.0
Deferred tax liabilities:
Fixed assets	(75.3)	(42.2)
Intangible assets	(8.3)	(7.5)
Other	0.0	(0.1)
Deferred tax liabilities	83.6	49.8
Net deferred tax assets	$ 425.6	$ 425.2

Revenue - Sales-type and Operating Lease Revenue (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Revenue from Contract with Customer [Abstract]
Sales-type lease revenue	$ 81.6	$ 69.8	$ 49.5
Operating lease revenue	$ 106.9	$ 51.4	$ 25.9

Stockholders' Equity - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Jan. 01, 2019
Equity, Class of Treasury Stock [Line Items]
Stock repurchase program, remaining authorized amount	$ 1,700,000,000
Aggregate reduction in common stock and additional paid-in capital during stock repurchases	14,500,000	$ 0	$ 152,000,000
Amount charged to retained earnings during stock repurchases	255,000,000	$ 0	$ 2,122,000,000
Common stock
Equity, Class of Treasury Stock [Line Items]
Stock repurchase program, authorized amount	$ 7,500,000,000
Stock Repurchase Program, increased to authorized amount				$ 2,000,000,000.0

Summary Of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Estimated Useful Lives Of The Assets

Property, plant, and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed on a straight-line basis over the estimated useful lives of the assets, generally, as follows:


			Useful Lives
Building			Up to 30 years
Building improvements			Up to 15 years
Leasehold improvements			Lesser of useful life or term of lease
Equipment and furniture			5 years
Operating lease assets			Greater of lease term or 1 to 5 years
Computer and office equipment			3 years
Enterprise-wide software			5 years
Purchased software			Lesser of 3 years or life of license


	December 31,
	2019		2018
Property, plant, and equipment, net:
Land	$	248.0	$	184.6
Building and building/leasehold improvements	408.3		266.2
Machinery and equipment	357.2		280.1
Operating lease assets—Intuitive System Leasing	293.8		150.2
Computer and office equipment	74.0		52.6
Capitalized software	182.2		157.8
Construction-in-process	272.5		156.7
Gross property, plant, and equipment	1,836.0		1,248.2
Less: Accumulated depreciation*	(563.1)		(436.2)
Total property, plant, and equipment, net	$	1,272.9	$	812.0

*Accumulated depreciation associated with operating lease assets—Intuitive System Leasing	(62.2)		(32.1)

Consolidated Financial Statement Details - Property, Plant and Equipment, Net (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Property, plant, and equipment, net:
Land	$ 248.0	$ 184.6
Building and building/leasehold improvements	408.3	266.2
Machinery and equipment	357.2	280.1
Operating lease assets—Intuitive System Leasing	293.8	150.2
Computer and office equipment	74.0	52.6
Capitalized software	182.2	157.8
Construction-in-process	272.5	156.7
Gross property, plant, and equipment	1,836.0	1,248.2
Less: Accumulated depreciation	(563.1)	(436.2)
Total property, plant, and equipment, net	1,272.9	812.0
Accumulated depreciation associated with operating lease assets - Intuitive System Leasing	$ (62.2)	$ (32.1)

Goodwill and Intangible Assets - Schedule of Intangible Assets (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 335.7	$ 247.4
Accumulated Amortization	(223.6)	(180.7)
Net Carrying Amount	112.1	66.7
Patents and developed technology
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	186.7	158.7
Accumulated Amortization	(149.0)	(144.7)
Net Carrying Amount	37.7	14.0
Distribution rights and others
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	91.3	40.2
Accumulated Amortization	(44.9)	(12.9)
Net Carrying Amount	46.4	27.3
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	57.7	48.5
Accumulated Amortization	(29.7)	(23.1)
Net Carrying Amount	$ 28.0	$ 25.4

Summary Of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2019

Dec. 31, 2018

Accounting Policies [Abstract]

Basis of Presentation

The accompanying Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and include the accounts of the Company and its wholly- and majority-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

Consolidation and Joint Ventures

The Consolidated Financial Statements include the results and balances of the Company’s majority-owned joint venture (“Joint Venture”) with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”). Chindex Medical Limited (“Chindex”), a subsidiary of Fosun Pharma, has been its distribution partner for da Vinci Surgical Systems in China. The Company holds a controlling financial interest in the Joint Venture, and the noncontrolling interest is reflected as a separate component of the consolidated stockholders’ equity. The noncontrolling interest’s share of the earnings in the Joint Venture is presented separately in the Consolidated Statements of Income for the years ended December 31, 2019 and 2018, while the amount was inconsequential for the year ended December 31, 2017, and was included as a component of interest and other income, net in the Consolidated Statements of Income.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and accompanying Notes to the Consolidated Financial Statements. The accounting estimates that require management’s most significant, difficult, and subjective judgments include the valuation and recognition of investments, revenue recognition and the valuation of revenue and allowances for sales returns and doubtful accounts, the estimation of exposures that are able to be hedged and the offsetting hedge transactions, the valuation of inventory, the valuation of and assessment of recoverability of intangible assets and their estimated useful lives, the valuation and recognition of share-based compensation, the recognition and measurement of current and deferred income tax assets, along with the assessment of recoverability, and liabilities, and the estimates for legal contingencies. Actual results could differ materially from these estimates.

Concentrations of Credit Risk and Other Risks and Uncertainties

The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximate fair value due to their short maturities. Marketable securities and derivative instruments are stated at their estimated fair values, based on quoted market prices for the same or similar instruments. The counterparties to the agreements relating to the Company’s investment securities and derivative instruments consist of various major corporations, financial institutions, municipalities, and government agencies of high credit standing.

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity from date of purchase of 90 days or less to be cash equivalents.

Restricted Cash

As of December 31, 2019, the Company had $15.0 million of restricted cash associated with its insurance programs. As of December 31, 2018, the Company had $51.5 million of restricted cash associated with its insurance programs and a shareholder litigation settlement that was reached in 2018. Restricted cash was included in prepaids and other current assets and intangible and other assets, net on the Consolidated Balance Sheets.

Investments

Available-for-sale investments. The Company’s investments may consist of U.S. treasury and U.S. government agency securities, taxable and tax-exempt municipal notes, corporate notes and bonds, commercial paper, non-U.S. government agency securities, and money market funds. The Company has designated all investments as available-for-sale and, therefore, such investments are reported at fair value, with unrealized gains and losses recorded in accumulated other comprehensive income (loss). For securities sold prior to maturity, the cost of securities sold is based on the specific identification method. Realized gains and losses on the sale of investments are recorded in interest and other income, net in the Consolidated Statements of Income. Investments with remaining maturities at date of purchase greater than 90 days and remaining maturities as of the reporting period less than one year are classified as short-term investments. Investments with remaining maturities greater than one year are classified as long-term investments.

Other-than-temporary impairment. All of the Company’s investments are subject to a periodic impairment review. The Company recognizes an impairment charge when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. Factors considered in determining whether a loss is temporary included the extent and length of time that the investment’s fair value has been lower than its cost basis, the financial condition and near-term prospects of the investee, the extent of the loss related to credit of the issuer, the expected cash flows from the security, the Company’s intent to sell the security, and whether or not the Company will be required to sell the security prior to the expected recovery of the investment’s amortized cost basis. No significant charges were recorded during the years ended December 31, 2019, 2018, and 2017.

Fair Value Measurements

The Company measures the fair value of money market funds and certain U.S. treasury securities based on quoted prices in active markets for identical assets as Level 1 securities. Marketable securities measured at fair value using Level 2 inputs are primarily comprised of commercial paper, corporate notes and bonds, U.S. and non-U.S. government agencies, and municipal notes. The Company reviews trading activity and pricing for these investments as of the measurement date. When sufficient quoted pricing for identical securities is not available, the Company uses market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data. This approach results in the Level 2 classification of these securities within the fair value hierarchy.

Inventory

Inventory is stated at the lower of cost or net realizable value on a first-in, first-out basis. Inventory costs include direct materials, direct labor, and normal manufacturing overhead. The cost basis of the Company’s inventory is reduced for any products that are considered excessive or obsolete based upon assumptions about future demand and market conditions.

Property, Plant, and Equipment


			Useful Lives
Building			Up to 30 years
Building improvements			Up to 15 years
Leasehold improvements			Lesser of useful life or term of lease
Equipment and furniture			5 years
Operating lease assets			Greater of lease term or 1 to 5 years
Computer and office equipment			3 years
Enterprise-wide software			5 years
Purchased software			Lesser of 3 years or life of license

Capitalized Software Costs for Internal Use

The Company capitalizes direct costs associated with developing or obtaining internal use software, including enterprise-wide business software, that are incurred during the application development stage. These capitalized costs are recorded as capitalized software within property, plant, and equipment. Costs related to preliminary project activities and post-implementation activities are expensed as incurred. Upon being placed in service, amounts capitalized are amortized over an estimated useful life of up to 5 years, generally on a straight-line basis.

Business Combinations

The Company accounts for business acquisitions in accordance with ASC 805, Business Combinations. This standard requires the acquiring entity in a business combination to recognize all of (and only) the assets acquired and liabilities assumed in the transaction and establishes the acquisition-date fair value as the measurement objective for all assets acquired and liabilities assumed in a business combination. Certain provisions of this standard prescribe, among other things, the determination of acquisition-date fair value of consideration paid in a business combination, including contingent consideration. The Company allocates the acquisition-date fair value to the assets acquired and liabilities assumed based on the estimated fair values. The excess of the acquisition-date fair value of consideration paid over the fair values of the identifiable assets and liabilities is recorded as goodwill. Acquisition-related costs are recognized separately from the business combination and are expensed as incurred. The Company includes the results of operations of the businesses that are acquired as of the acquisition date.

Goodwill and Intangible Assets

Goodwill and intangible assets with indefinite useful lives are not amortized but are tested for impairment at least annually during the fourth quarter, or if circumstances indicate their value may no longer be recoverable. Goodwill represents the excess of the purchase price over the fair value of net identifiable assets and liabilities. The Company continues to operate in one segment, which is considered to be the sole reporting unit and, therefore, goodwill was tested for impairment at the enterprise level.

Intangible assets are carried at cost, net of accumulated amortization. The Company does not have intangible assets with indefinite useful lives other than goodwill. Amortization is recorded on a straight-line basis over the intangible assets’ useful lives, which range from approximately 1 to 9 years.

Impairment of Long-lived Assets

The Company evaluates long-lived assets, which include amortizable intangible and tangible assets, for impairment whenever events or changes in circumstances indicate that the carrying value of long-lived assets may not be recoverable. Recoverability is measured by comparing the net book value to the future undiscounted cash flows attributable to such assets. The Company recognizes an impairment charge equal to the amount by which the net book value exceeds its fair value. No material impairment losses were incurred in the periods presented.

Revenue

Revenue Recognition

The Company’s revenue consists of product revenue resulting from the sale of systems, system components, instruments and accessories, and service revenue. The Company accounts for a contract with a customer when there is a legally enforceable contract between the Company and its customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. The Company’s revenues are measured based on the consideration specified in the contract with each customer, net of any sales incentives and taxes collected from customers that are remitted to government authorities.

The Company’s system sale arrangements generally contain multiple products and services. For these bundled sale arrangements, the Company accounts for individual products and services as separate performance obligations if they are a distinct product or service that is separately identifiable from other items in bundled packages and if a customer can benefit from the product or service on its own or with other resources that are readily available to the customer. The Company’s system sale arrangements include a combination of the following performance obligations: system(s); system components; system accessories; instruments; accessories; and system service. The Company’s system sale arrangements generally include a five-year period of service. The first year of service is generally free and included in the system sale arrangement, and the remaining four years are generally included at a stated service price. The Company considers the service terms in the arrangements that are legally enforceable to be performance obligations. Other than service, the Company generally satisfies all of the performance obligations up-front. System components, system accessories, instruments, accessories, and service are also sold on a stand-alone basis.

The Company recognizes revenue as the performance obligations are satisfied by transferring control of the product or service to a customer. The Company generally recognizes revenue for the performance obligations at the following points in time:

System sales. For systems (including system components and system accessories) sold directly to end customers, revenue is recognized when the Company transfers control to the customer, which is generally at the point when acceptance occurs that indicates customer acknowledgment of delivery or installation, depending on the terms of the arrangement. For systems sold through distributors, revenue is recognized generally at the time of shipment. The Company’s system arrangements generally do not provide a right of return. The systems are generally covered by a one-year warranty. Warranty costs were not material for the periods presented.

Instruments and accessories. Revenue from sales of instruments and accessories is recognized when control is transferred to the customers, which generally occurs at the time of shipment but also occurs at the time of delivery, depending on the customer arrangement. The Company allows its customers in the normal course of business to return unused products for a limited period of time subsequent to initial purchase and records an allowance against revenue for estimated returns.

Service. Service revenue is recognized over the term of the service period, as the customer benefits from the services throughout the service period. Revenue related to services performed on a time-and-materials basis is recognized when performed.

The Company offers its customers the opportunity to trade in their older systems for a credit towards the purchase of a newer generation system. The Company generally does not provide specified price trade-in rights or upgrade rights at the time of system purchase. Such trade-in or upgrade transactions are separately negotiated based on the circumstances at the time of the trade-in or upgrade, based on the then fair value of the system, and are generally not based on any pre-existing rights granted by the Company. Accordingly, such trade-ins and upgrades are not considered separate performance obligations in the arrangement for a system sale. Traded-in systems could be reconditioned and resold. The Company accounts for the fair value of the traded-in system in the total consideration in the arrangement by including the net realizable value of the traded-in system less a normal profit margin. The value of the traded-in system is determined as the amount, after reconditioning costs are added, that will allow a normal profit margin on the sale of the reconditioned unit to be generated. When there is no market for the traded-in units, no value is assigned. Traded-in units are reported as a component of inventory until resold, or otherwise disposed.

In addition, customers may also have the opportunity to upgrade their systems at a price determined at the time of the upgrade, for example, by adding a second surgeon console for use with the da Vinci Surgical System. Such upgrades are performed by completing component level upgrades at the customer’s site. Upgrade revenue is recognized when the component level upgrades are complete and all revenue recognition criteria are met.

For multiple-element arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. If a standalone selling price is not directly observable, then the Company estimates the standalone selling price considering market conditions and entity-specific factors including, but not limited to, features and functionality of the products and services, geographies, and type of customer. The Company regularly reviews standalone selling prices and updates these estimates as necessary.

Assets Recognized from the Costs to Obtain a Contract with a Customer

The Company has determined that certain sales incentives provided to the Company’s sales team are required to be capitalized when the Company expects to generate future economic benefits from the related revenue-generating contracts subsequent to the initial capital sales transaction. When determining the economic life of the contract acquisition assets recognized, the Company considers historical service renewal rates, expectations of future customer renewals of service contracts, and other factors that could impact the economic benefits that the Company expects to generate from the relationship with its customers. The costs capitalized as contract acquisition costs included in intangible and other assets, net in the Consolidated Balance Sheets were $51.5 million and $34.2 million as of December 31, 2019, and 2018, respectively. The Company did not incur any impairment losses during the periods presented.

Lessor, Leases

Intuitive System Leasing

The Company enters into sales-type and operating lease arrangements with certain qualified customers. Sales-type leases have terms that generally range from 24 to 84 months and are usually collateralized by a security interest in the underlying assets. Revenue related to multiple-element arrangements are allocated to lease and non-lease elements based on their relative standalone selling prices as prescribed by the Company’s revenue recognition policy. Lease elements generally include a system or system component, while non-lease elements generally include service, instruments, and accessories. For some lease arrangements, the customers are provided with the right to purchase the leased system at some point during and/or at the end of

the lease term. Except for certain usage-based lease arrangements, lease arrangements generally do not provide rights for the customers to exit or terminate the lease without incurring a penalty. For some leases, lease payments are based on the usage of the systems.

In determining whether a transaction should be classified as a sales-type or operating lease, the Company considers the following terms at lease commencement: (1) whether title of the system transfers automatically or for a nominal fee by the end of the lease term, (2) whether the present value of the minimum lease payments equals or exceeds substantially all of the fair value of the leased system, (3) whether the lease term is for the major part of the remaining economic life of the leased system, (4) whether the lease grants the lessee an option to purchase the leased system that the lessee is reasonably certain to exercise, and (5) whether the underlying system is of such a specialized nature that it is expected to have no alternative use to the Company at the end of the lease term.

The Company generally recognizes revenue from sales-type lease arrangements at the time the system is accepted by the customer, assuming all other revenue recognition criteria have been met. Revenue related to lease elements from sales-type leases is presented as product revenue. Revenue related to lease elements from operating lease arrangements is generally recognized on a straight-line basis over the lease term or based upon system usage and is presented as product revenue.

Lessee, Leases

Other Leasing Arrangements

The Company determines if an arrangement contains a lease at inception. For arrangements where the Company is the lessee, operating leases are included in intangible and other assets, net, other accrued liabilities, and other long-term liabilities on the Consolidated Balance Sheet as of December 31, 2019. The Company currently does not have any finance leases.

Operating lease right-of-use ("ROU") assets and operating leases liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the lease liabilities, as the Company's leases generally do not provide an implicit rate. Lease terms may include options to extend or terminate when the Company is reasonably certain the option will be exercised. Lease expense is recognized on a straight-line basis over the lease term.

The Company also has lease arrangements with lease and non-lease components. The Company elected the practical expedient not to separate non-lease components from lease components for the Company's real estate and automobile leases. Additionally, the Company applied a portfolio approach to effectively account for the operating lease ROU assets and lease liabilities for the Company's automobile leases. The Company also elected to apply the short-term lease measurement and recognition exemption in which ROU assets and lease liabilities are not recognized for leases with terms of 12 months or less.

Allowance for Sales Returns and Doubtful Accounts

Allowances for Sales Returns and Doubtful Accounts

The allowance for sales returns is based on the Company’s estimates of potential future returns of certain products and other allowances related to current period product revenue. The Company analyzes historical returns, current economic trends, and changes in customer demand and acceptance of the Company’s products. The allowance for doubtful accounts is based on the Company’s assessment of the collectability of customer accounts. The Company regularly reviews the allowance by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect a customer’s ability to pay.

Share-Based Compensation

The Company accounts for share-based employee compensation plans using the fair value recognition and measurement provisions under U.S. GAAP. The Company’s share-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as expense on a straight-line basis over the requisite service period. The Company estimates expected forfeitures at the time of grant and revises the estimate, if necessary, in subsequent periods if actual forfeitures differ from those estimated.

Expected Term: The expected term represents the weighted-average period that the stock options are expected to be outstanding prior to being exercised. The Company determines expected term based on historical exercise patterns and its expectation of the time that it will take for employees to exercise options still outstanding.

Expected Volatility: The Company uses market-based implied volatility for purposes of valuing stock options granted. Market-based implied volatility is derived based on actively traded options with expirations greater than one year on the Company’s common stock. The extent to which the Company relies on market-based volatility when valuing options depends, among other things, on the availability of traded options on the Company’s stock and the term of such options. Due to sufficient volume of the traded options, the Company used 100% market-based implied volatility to value options granted, which the Company believes is more representative of future stock price trends than historical volatility.

Risk-Free Interest Rate: The risk-free interest rate is based on the U.S. treasury yield curve in effect at the time of grant for the expected term of the stock option.

The fair value of restricted stock units is determined based on the closing quoted price of the Company’s common stock on the date of the grant. See “Note 9. Share-Based Compensation,” for a detailed discussion of the Company’s stock plans and share-based compensation expense.

Computation of Net Income per Share

Basic net income per share attributable to Intuitive Surgical, Inc. is computed using the weighted-average number of shares outstanding during the period. Diluted net income per share attributable to Intuitive Surgical, Inc. is computed using the weighted-average number of the Company’s shares and dilutive potential shares outstanding during the period. Dilutive potential shares primarily consist of employee stock options, restricted stock units, and shares to be purchased by employees under the Company’s employee stock purchase plan.

U.S. GAAP requires that employee equity share options, non-vested shares, and similar equity instruments granted by the Company be treated as potential common shares outstanding in computing diluted earnings per share. Diluted shares outstanding include the dilutive effect of equity awards, which is calculated based on the average share price for each fiscal period using the treasury stock method. Under the treasury stock method, the amount the employee must pay for exercising stock options and the amount of compensation cost for future service that the Company has not yet recognized are assumed to be used to repurchase shares.

Research and Development Expenses

Research and development costs are expensed as incurred and include amortization of intangible assets, costs associated with co-development research and development licensing arrangements, costs of prototypes, salaries, benefits and other headcount-related costs, contract and other outside service fees, and facilities and overhead costs.

Foreign Currency and Other Hedging Instruments

For subsidiaries whose local currency is their functional currency, their assets and liabilities are translated into U.S. dollars at exchange rates at the balance sheet date, and revenues and expenses are translated using average exchange rates in effect during the period. Gains and losses from foreign currency translation are included in accumulated other comprehensive income (loss) within stockholders’ equity in the Consolidated Balance Sheets. For all non-functional currency account balances, the re-measurement of such balances to the functional currency results in either a foreign exchange gain or loss, which is recorded to interest and other income, net in the Consolidated Statements of Income in the same accounting period that the re-measurement occurred.

The Company uses derivatives to partially offset its business exposure to foreign currency exchange risk. The terms of the Company’s derivative contracts are generally twelve months or shorter. The Company typically hedges portions of its forecasted foreign currency exposure associated with revenue and expenses. The Company may also enter into foreign currency forward contracts to offset the foreign currency exchange gains and losses generated by re-measurement of certain assets and liabilities denominated in non-functional currencies. The hedging program is not designated for trading or speculative purposes.

The Company’s accounting policies for these instruments are based on whether the instruments are designated as hedging or non-hedging instruments. The Company records all derivatives on the Consolidated Balance Sheets at fair value. The effective portions of cash flow hedges are recorded in other comprehensive income (loss) (“OCI”) until the hedged item is recognized in earnings. Derivative instruments designated as cash flow hedges are de-designated as hedges when it is probable that the forecasted hedged transaction will not occur in the initially identified time period or within a subsequent two-month time period. Gains and losses in OCI associated with such derivative instruments are reclassified immediately into earnings through interest and other income, net. Any subsequent changes in fair value of such derivative instruments also are reflected in current earnings.

Derivatives that are not designated as hedging instruments and the ineffective portions of cash flow hedges are adjusted to fair value through earnings in interest and other income, net.

Income Taxes

Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amounts that are expected more likely than not to be realized in the future.

The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such positions are then measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement.

The Company recognizes excess tax benefits and tax deficiencies in the provision for income taxes as discrete items in the period when the awards vest or are settled. The Company accounts for Global Intangible Low-Taxed Income (“GILTI”) as period costs when incurred.

Segments

The Company operates in one segment. Management uses one measurement of profitability and does not segregate its business for internal reporting. As of December 31, 2019, and 2018, 85% and 88% of long-lived assets were in the United States, respectively. Revenue is attributed to a geographic region based on the location of the end customer.

Legal Contingencies

From time to time, the Company is involved in a number of legal proceedings involving product liability, intellectual property, shareholder derivative actions, securities class actions, and other matters. A liability and related charge are recorded to earnings in the Company’s consolidated financial statements for legal contingencies when the loss is considered probable and the amount can be reasonably estimated. The assessment is re-evaluated each period and is based on all available information, including discussion with outside legal counsel. If a reasonable estimate of a known or probable loss cannot be made, but a range of probable losses can be estimated, the low-end of the range of losses is recognized if no amount within the range is a better estimate than any other. If a material loss is reasonably possible but not probable and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the consolidated financial statements. The Company expenses legal fees as incurred.

When determining the estimated probable loss or range of losses, significant judgment is required to be exercised in order to estimate the amount and timing of the loss to be recorded. Estimates of probable losses resulting from litigation are inherently difficult to make, particularly when the matters are in early procedural stages with incomplete facts and information. The final outcome of legal proceedings is dependent on many variables that are difficult to predict and, therefore, the ultimate cost to entirely resolve such matters may be materially different than the amount of current estimates. Consequently, new information or changes in judgments and estimates could have a material adverse effect on the Company’s business, financial condition, and results of operations or cash flows.

Recent Accounting Pronouncements

Recently Adopted Accounting Pronouncements

Leases

In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-02, Leases (Topic 842) (“Topic 842”), which amended prior accounting standards for leases. The Company adopted Topic 842 on January 1, 2019, using the alternative modified transition method, which requires a cumulative-effect adjustment, if any, to the opening balance of retained earnings to be recognized on the date of adoption with prior periods not restated. There was no cumulative-effect adjustment recorded on January 1, 2019. Please see the description of the Company's "Intuitive System Leasing" and "Other Leasing Arrangements" accounting policies above. Also, see "Note 6. Leases" for further information.

As permitted by the new standard, the Company elected the following practical expedients when assessing the transition impact from both the lessee and lessor perspectives: (i) not to reassess whether any expired or existing contracts as of January 1, 2019, are or contain leases; (ii) not to reassess the lease classification for any expired or existing leases as of January 1, 2019; (iii) not to reassess initial direct costs for any existing leases as of January 1, 2019; and (iv) not to reassess whether land easements meet the definition of a lease.

The primary impact for the Company was the balance sheet recognition of ROU assets and lease liabilities for operating leases as a lessee.

Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract

In August 2018, the FASB issued ASU No. 2018-15, Intangibles (Topic 350): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, which aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. This standard also requires customers to amortize the capitalized implementation costs of a hosting arrangement that is a service contract over the term of the hosting arrangement. The Company early adopted this standard, as of January 1, 2019, on a prospective basis for all applicable implementation costs.

The Company recorded these capitalized implementation costs within intangible and other assets, net in the accompanying Consolidated Balance Sheets and recognized the related amortization expenses generally over the fixed, non-cancellable term of the associated arrangement on a straight-line basis. The adoption did not have a material impact on the Company's financial position and the results of operations in 2019.

Recent Accounting Pronouncements Not Yet Adopted

Financial Instruments (Topic 326)

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments ("ASU 2016-13"), which requires an entity to measure expected credit losses for certain financial instruments and financial assets, including trade receivables. This standard also modifies the impairment model for available-for-sale debt securities and requires that credit losses be recorded through an allowance for credit losses and limits the credit loss to the amount by which fair value is below amortized cost. The Company will adopt ASU 2016-13 as of January 1, 2020, using the modified retrospective transition method. The adoption of ASU 2016-13 is not expected to have a material impact on the Company's financial position and the results of operations.

Beginning in 2018, the Company adopted Accounting Standards Update (“ASU”) No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other than Inventory. The Company adopted this standard using the modified retrospective approach and, as a result, recorded a cumulative adjustment to retained earnings as of January 1, 2018.

Revenue - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Revenue from Contract with Customer [Abstract]
Revenue recognized	$ 307	$ 269

Leases - Schedule of Contractual Maturities of Gross Lease Receivables (Details) $ in Millions	Dec. 31, 2019 USD ($)
Leases [Abstract]
2020	$ 63.5
2021	52.9
2022	36.2
2023	22.1
2024	15.4
2025 and thereafter	1.8
Total	$ 191.9

Leases - Maturities of Operating Lease Payments (Details) $ in Millions	Dec. 31, 2019 USD ($)
Leases [Abstract]
2020	$ 146.5
2021	134.2
2022	116.0
2023	86.6
2024	40.6
2025 and thereafter	10.8
Total	$ 534.7

Consolidated Financial Statement Details - Other Long-Term Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Income taxes—long-term	$ 258.6	$ 270.2
Deferred revenue—long-term	27.4	33.0
Other long-term liabilities	132.3	35.4
Total other long-term liabilities	$ 418.3	$ 338.6

Leases - Schedule of Future Minimum Lease Receivables Under Operating Leases (Details) $ in Millions	Dec. 31, 2018 USD ($)
Leases [Abstract]
2019	$ 88.0
2020	85.8
2021	68.8
2022	51.3
2023	25.4
2024 and thereafter	1.9
Total	$ 321.2

Share-Based Compensation - Additional Information (Details) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2019 USD ($) period $ / shares shares	Dec. 31, 2018 USD ($) shares	Dec. 31, 2017 USD ($) shares	Dec. 31, 2016	Apr. 30, 2019 shares	Mar. 31, 2019 shares	Apr. 30, 2017 shares	Mar. 31, 2017 shares	Apr. 30, 2015 shares	Mar. 31, 2015 shares	Oct. 31, 2009 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate intrinsic value of options exercised under stock option plans \| $	$ 512.0	$ 526.6	$ 379.9
Cash received from option exercises and employee stock purchase plans \| $	$ 272.8	236.6	415.5
Number of options vested and expected to vest	5,200,000
Weighted average remaining contractual life of shares vested and expected to vest, years	5 years 2 months 12 days
Aggregate intrinsic value of shares vested and expected to vest \| $	$ 1,833.1
Options vested and expected to vest, weighted-average exercise price per share \| $ / shares	$ 241.65
Share-based compensation charges, income tax effect \| $	$ 70.2	54.3	49.2
Employee Service Share-based Compensation, Tax Benefit from Exercise of Stock Options \| $	109.7
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation expense \| $	$ 493.6
Weighted average period unrecognized compensation expenses are expected to be recognized, years	2 years 2 months 12 days
Expected to vest (in shares)	1,700,000
Aggregate intrinsic value \| $	$ 1,032.0
Canceled (shares)	100,000
Vested in period, aggregate fair value \| $	$ 433.2	$ 334.3	$ 144.2
Restricted Stock Units (RSUs) \| Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	25.00%
Share based vesting period	4 years
Annual Grant Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage vesting upon six months of service	12.50%
Percentage vesting per month after six months of service	2.0833%
Annual Grant Options \| February Grant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage vesting upon six months of service	12.50%
Percentage vesting per month after six months of service	2.0833%
Annual Grant Options \| August Grant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage vesting at the end of one month	14.5833%
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	2.0833%
New Hire Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage vesting upon one year of service	25.00%
Percentage vesting per month after one year	2.0833%
Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares were reserved for future issuance (shares)	1,200,000
Minimum hours employed per week	20 hours
Minimum months employed per year	5 months
Maximum percentage of employees on stockholders to participate in ESPP	5.00%
Percentage of employee payroll deduction under the stock plan, maximum	15.00%
Duration for each offering period	24 months
Number of shorter purchase periods that each offering period is divided into \| period	4
Duration of each shorter offering period	6 months
Discount on fair market value on the offering date	85.00%
Discount on fair market value on the purchase date	85.00%
Period of look-back that could cause offering period to reset	2 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant							7,590,315	6,090,315
Employee stock purchase plan, shares issued	200,000	200,000	200,000
Employee stock purchase plan, value of shares issued \| $	$ 56.4	$ 46.8	$ 38.3
Total unrecognized compensation expense \| $	$ 31.4
Weighted average period unrecognized compensation expenses are expected to be recognized, years	1 year 4 months 24 days
Nonvested Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation expense \| $	$ 110.1
Weighted average period unrecognized compensation expenses are expected to be recognized, years	2 years 6 months
Initial RSU grants \| Director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		33.3333%
2010 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, options, expiration term (in years)	10 years
Number of shares of common stock reserved for issuance (shares)					28,450,000	24,450,000
Shares were reserved for future issuance (shares)	5,900,000
2010 Plan \| Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares were reserved for future issuance (shares)	2,600,000
2010 Plan \| Annual Grant Options \| February Grant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based vesting period	4 years
2010 Plan \| Annual Grant Options \| August Grant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based vesting period	3 years 6 months
2009 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, options, expiration term (in years)	10 years
Number of shares of common stock reserved for issuance (shares)									4,365,000	3,465,000
2000 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, options, expiration term (in years)	10 years
Minimum exercise price of NSOs, percentage of fair value	85.00%
2000 Non-Employee Directors' Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, options, expiration term (in years)	10 years
Number of shares of common stock reserved for issuance (shares)											450,000
Shares were reserved for future issuance (shares)	100,000
2000 Non-Employee Directors' Stock Option Plan \| Annual Grant Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based vesting period				1 year
2000 Non-Employee Directors' Stock Option Plan \| Initial Grant Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage vesting upon one year of service		33.3333%
Percentage vesting per month after one year		2.7778%
Stock options granted initial vesting period, years				3 years

Income Taxes

12 Months Ended

Dec. 31, 2019

Income Tax Disclosure [Abstract]

Income Taxes

INCOME TAXES

Income before provision for income taxes for the years ended December 31, 2019, 2018, and 2017, consisted of the following (in millions):


	Years Ended December 31,
	2019		2018		2017
U.S.	$	1,053.7	$	852.7	$	774.7
Foreign	448.5		426.8		330.1
Total income before provision for income taxes	$	1,502.2	$	1,279.5	$	1,104.8

The provision for income taxes for the years ended December 31, 2019, 2018, and 2017, consisted of the following (in millions):


	Years Ended December 31,
	2019		2018		2017
Current
Federal	$	82.0	$	89.5	$	352.1
State	26.5		21.1		13.0
Foreign	18.0		9.9		8.7
	$	126.5	$	120.5	$	373.8
Deferred
Federal	$	8.5	$	(4.1)	$	62.8
State	3.2		(0.3)		(0.3)
Foreign	(17.8)		38.4		(2.4)
	$	(6.1)	$	34.0	$	60.1
Total income tax expense	$	120.4	$	154.5	$	433.9

Income tax expense differs from amounts computed by applying the statutory federal income rate of 21% for the years ended December 31, 2019, and 2018, and 35% for the year ended December 31, 2017, as a result of the following (in millions):


	Years Ended December 31,
	2019		2018		2017
Federal tax at statutory rate	$	315.5	$	268.7	$	386.7
Increase (reduction) in tax resulting from:
State taxes, net of federal benefits	29.7		20.8		16.0
Foreign rate differential	(56.2)		(44.7)		(115.7)
U.S. tax on foreign earnings	55.0		43.7		8.4
Research and development credit	(32.7)		(25.2)		(15.3)
Share-based compensation not benefited	13.5		9.9		10.8
Domestic production activities deduction	—		—		(7.9)
Reversal of unrecognized tax benefits	(8.4)		(5.2)		(62.4)

Tax Cuts and Jobs Act impact	—		0.5		317.8
Excess tax benefits related to share-based compensation arrangements	(146.5)		(116.2)		(102.8)
Deferred tax remeasurement due to Swiss Tax Reform	(51.3)		—		—
Other	1.8		2.2		(1.7)
Total income tax expense	$	120.4	$	154.5	$	433.9

Deferred income taxes reflect tax carry forwards and the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets and liabilities are as follows (in millions):


	December 31,
	2019		2018
Deferred tax assets:
Share-based compensation expense	$	95.6	$	87.2
Expenses deducted in later years for tax purposes	42.0		29.1
Intangible assets	362.3		351.9
Research and other credits	56.1		40.1
Other	10.4		9.0
Gross deferred tax assets	$	566.4	$	517.3
Valuation allowance	(57.2)		(42.3)
Deferred tax assets	$	509.2	$	475.0
Deferred tax liabilities:
Fixed assets	$	(75.3)	$	(42.2)
Intangible assets	(8.3)		(7.5)
Other	—		(0.1)
Deferred tax liabilities	$	(83.6)	$	(49.8)
Net deferred tax assets	$	425.6	$	425.2

In December 2017, the 2017 Tax Act was enacted, which includes a number of changes in existing tax law impacting businesses, including a one-time deemed repatriation of cumulative undistributed foreign earnings and a permanent reduction in the U.S. federal statutory rate from 35% to 21%, effective on January 1, 2018. The Securities Exchange Commission (“SEC”) issued guidance for a measurement period of one year from the enactment date to finalize the accounting for effects of the 2017 Tax Act. The Company recorded an income tax expense of $317.8 million in its 2017 income tax provision related to the 2017 Tax Act, which included a provisional estimate of $270.2 million related to the one-time deemed repatriation toll charge (“Toll Tax”) and a provisional estimate of $47.6 million income tax expense due to the re-measurement of its net deferred tax assets at a reduced U.S. federal statutory rate of 21%. In December 2018, the Company completed its accounting for the effect of the 2017 Tax Act within the measurement period under the SEC guidance and reflected a net $0.5 million increase in the 2018 income tax expense.

The Company repatriated $1.6 billion of its cumulative undistributed foreign earnings back to the U.S. in June 2018 without any significant U.S. income tax consequences. The Company intends to repatriate earnings from its Swiss subsidiary as needed, since the U.S. and foreign tax implications of such repatriations are not expected to be significant. The Company will continue to indefinitely reinvest earnings from the rest of our foreign subsidiaries, which are not significant.

The Company’s tax holiday obtained in 2007 for business operations in Switzerland ended on December 31, 2017. The Company received a new tax ruling in Switzerland for new business operations. The new ruling is effective for years 2018 through 2022, which will be extended for the next five years thereafter to the extent certain terms and conditions continue to be met. The new ruling allows for a reduced cantonal tax rate based on various thresholds of investment, including the ownership, development, and use of the non-U.S. intellectual property rights and employment in such jurisdiction. The tax benefits from Swiss tax holidays for the years ended December 31, 2019, and 2018, were insignificant, while for the year ended December 31, 2017, was approximately $10.9 million, or $0.09 per diluted share.

In August 2019, Swiss tax reform was enacted, which resulted in a higher statutory rate for the Company's Swiss entity for years after 2019. The Company remeasured its Swiss deferred tax asset at the enacted tax rate and recorded an income tax benefit of $51.3 million in its 2019 tax provision.

As of December 31, 2019, and 2018, the Company had valuation allowances of $57.2 million and $42.3 million, respectively, primarily related to California deferred tax assets generated by California R&D credit forwards, which have no expiration period. The Company recorded a valuation allowance against its California deferred tax assets, as it is more likely than not these deferred tax assets will not be realized as a result of the computation of California taxes under the single sales factor.

The Company recorded a net increase of its gross unrecognized tax benefits of $17.9 million during the year ended December 31, 2019. The net increase was primarily due to increases related to 2019 uncertain tax positions, partially offset by the reversal of gross unrecognized tax benefits in connection with the expiration of certain statutes of limitation in various

jurisdictions and an audit conclusion. The Company had gross unrecognized tax benefits of approximately $96.7 million, $78.8 million, and $65.4 million as of December 31, 2019, 2018, and 2017, respectively, which, if recognized, would result in a reduction of the Company’s effective tax rate. The Company included interest expense accrued on unrecognized tax benefits as a component of its income tax expense. As of December 31, 2019, 2018, and 2017, gross interest related to unrecognized tax benefits accrued was $2.9 million, $2.6 million, and $1.8 million, respectively. A majority of the Company’s net unrecognized tax benefits and related interest is presented in other long-term liabilities on the Consolidated Balance Sheets.

A reconciliation of the beginning and ending amounts of gross unrecognized income tax benefits for the years ended December 31, 2019, 2018, and 2017, are as follows (in millions):


	Years Ended December 31,
	2019		2018		2017
Beginning balance	$	78.8	$	65.4	$	106.0
Increases related to tax positions taken during the current year	26.5		22.5		21.1

Increases related to tax positions taken during a prior year	1.2		—		—
Decreases related to tax positions taken during a prior year	—		(0.9)		(46.5)
Decreases related to settlements with tax authorities	(3.8)		—		(0.5)
Decreases related to expiration of statute of limitations	(6.0)		(8.2)		(14.7)
Ending balance	$	96.7	$	78.8	$	65.4

The Company files federal, state, and foreign income tax returns in many U.S. and OUS jurisdictions. Years before 2016 are closed for the significant jurisdictions. Certain of the Company’s unrecognized tax benefits could change due to activities of various tax authorities, including potential assessment of additional tax, possible settlement of audits, or through normal expiration of various statutes of limitations, which could affect the Company’s effective tax rate in the period in which they change. Due to the uncertainty related to the timing and potential outcome of audits, the Company cannot estimate the range of reasonably possible change in unrecognized tax benefits that may occur in the next 12 months.

The Company is subject to the examination of its income tax returns by the Internal Revenue Service and other tax authorities. The outcome of these audits cannot be predicted with certainty. The Company’s management regularly assesses the likelihood of adverse outcomes resulting from these examinations to determine the adequacy of the Company’s provision for income taxes. If any issues addressed in the Company’s tax audits are resolved in a manner not consistent with management’s expectations, the Company could be required to adjust its provision for income taxes in the period such resolution occurs.

In July 2015, a U.S. Tax Court opinion (the “2015 Opinion”) was issued involving an independent third party related to intercompany charges for share-based compensation. Based on the findings of the U.S. Tax Court, the Company was required to, and did, refund to its foreign subsidiaries the share-based compensation element of certain intercompany charges made in prior periods. Starting in 2015, direct share-based compensation has been excluded from intercompany charges. In June 2019, the Ninth Circuit Court of Appeals (the "Ninth Circuit") reversed the 2015 Opinion (the “Ninth Circuit Opinion”). Subsequently, a re-hearing of the case was requested, but the rehearing request was denied by the Ninth Circuit on November 12, 2019. However, a petition for appeal to the U.S. Supreme Court can be filed within 90 days of the denial. Since the Ninth Circuit Opinion potentially is subject to further judicial review, the Company continues to treat its share-based compensation expense in accordance with the 2015 Opinion and continues to recognize the related tax benefits in its financial statements based upon its evaluation of the position in light of the present facts. In the event of a final opinion that reverses the 2015 Opinion, there may be an adverse impact to the Company’s income tax expense and effective tax rate.

Income Taxes - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended		3 Months Ended								12 Months Ended
	Aug. 31, 2019	Jun. 30, 2018	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Tax Holiday [Line Items]
Provisional income tax expense											$ 0.0	$ 0.5	$ 317.8
U.S. tax on foreign earnings											55.0	43.7	8.4
Tax Cuts and Jobs Act of 2017, Change in Tax Rate, Income Tax Expense (Benefit)													47.6
Estimated cumulative undistributed foreign earnings		$ 1,600.0
Deferred tax remeasurement due to Swiss Tax Reform	$ 51.3										51.3	0.0	0.0
Valuation allowance			$ (57.2)				$ (42.3)				(57.2)	(42.3)
Effective Income Tax Rate Reconciliation, Share-based Compensation, Excess Tax Benefit, Amount			33.7	$ 28.8	$ 11.3	$ 72.7	15.8	$ 24.1	$ 21.6	$ 54.7	146.5	116.2	102.8
Total gross unrecognized tax benefits			96.7				78.8				96.7	78.8	65.4	$ 106.0
Net increase in gross unrecognized tax benefits											17.9
Interest and penalties related to unrecognized tax benefits accrued			$ 2.9				$ 2.6				$ 2.9	$ 2.6	1.8
Swiss Federal Tax Administration (FTA)
Income Tax Holiday [Line Items]
Tax benefit from tax holiday													$ 10.9
Tax benefit from tax holiday (in dollars per share)													$ 0.09
Pro forma
Income Tax Holiday [Line Items]
U.S. tax on foreign earnings													$ 270.2

Consolidated Financial Statement Details - Supplemental Cash Flow Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Supplemental Cash Flow Elements [Abstract]
Income taxes paid	$ 158.6	$ 179.2	$ 147.5
Supplemental non-cash investing and financing activities:
Deferred payments and contingent consideration related to business combinations	86.6	16.7	0.0
Property, Plant and Equipment, Transfers and Changes	$ 210.6	$ 125.7	$ 65.8

Employee Benefit Plans - Additional Information (Details)	12 Months Ended
	Dec. 31, 2019 USD ($)
Retirement Benefits [Abstract]
Maximum rate of employees' contribution to 401(k) plan	100.00%
Employer match percentage	200.00%
Employer matching contributions	$ 1,500

Leases

12 Months Ended

Dec. 31, 2019

Leases [Abstract]

Leases

LEASES

Lessor Information related to Intuitive System Leasing

Sales-type Leases. Lease receivables relating to sales-type lease arrangements are presented on the Consolidated Balance Sheets as follows (in millions):


	December 31,
	2019		2018
Gross lease receivables	$	191.9	$	150.4
Unearned income	(10.1)		(6.3)
Allowance for credit loss	(1.2)		(1.0)
Net investment in sales-type leases	$	180.6	$	143.1
Reported as:
Prepaids and other current assets	$	63.1	$	51.2
Intangible and other assets, net	117.5		91.9
Total, net	$	180.6	$	143.1

Contractual maturities of gross lease receivables as of December 31, 2019, are as follows (in millions):


Fiscal Year	Amount

2020	$	63.5
2021	52.9
2022	36.2
2023	22.1
2024	15.4
2025 and thereafter	1.8
Total	$	191.9

Operating Leases. The Company’s operating lease terms are generally less than seven years. Future minimum lease payments related to the non-cancellable portion of operating leases (which excludes contingent payments related to usage-based arrangements) as of December 31, 2019, are as follows (in millions):


Fiscal Year	Amount

2020	$	146.5
2021	134.2
2022	116.0
2023	86.6
2024	40.6
2025 and thereafter	10.8
Total	$	534.7

Contingent rental revenue relating to operating lease arrangements was not material for the years ended December 31, 2019, 2018, and 2017.

Lessee Information

The Company enters into operating leases for real estate, automobiles, and certain equipment. Operating lease expense was $19.1 million for the year ended December 31, 2019. For leases with terms of 12 months or less, the related expense for the year ended December 31, 2019 was not material.

Supplemental cash flow information for the year ended December 31, 2019, related to operating leases was as follows (in millions):


	Amount
Cash paid for leases that were included within operating cash outflows	$	18.8
Right-of-use assets recognized related to new lease obligations	$	21.5

Supplemental balance sheet information, as of December 31, 2019, related to operating leases was as follows (in millions, except lease term and discount rate):


Reported as:	Amount
Intangible and other assets, net (Right-of-use assets)	$	74.4
Other accrued liabilities	$	7.7
Other long-term liabilities	68.7
Total lease liabilities	$	76.4
Weighted average remaining lease term	6.1 years
Weighted average discount rate	3.4		%

As of December 31, 2019, the future payments related to the Company's operating lease liabilities are scheduled as follows (in millions):


Fiscal Year	Amount
2020	$	9.6
2021	19.7
2022	14.7
2023	12.8
2024	8.4
2025 and thereafter	22.4
Total lease payments	$	87.6
Less imputed interest	(11.2)
Total operating lease liabilities	$	76.4

ASC 840 Disclosures

The Company elected the alternative modified transition method and is required to present previously disclosed information under the prior accounting standards for leases.

Lessor Information

Sales-type Leases. Contractual maturities of gross lease receivables as of December 31, 2018, are as follows (in millions):


Fiscal Year	Amount
2019	$	50.8
2020	46.5
2021	29.7
2022	14.9
2023	7.5
2024 and thereafter	1.0
Total lease payments	$	150.4

Operating Leases. Future minimum lease payments related to the non-cancellable portion of operating leases (which excludes contingent payments related to usage-based arrangements) as of December 31, 2018, are as follows (in millions):


Fiscal Year	Amount
2019	$	88.0
2020	85.8
2021	68.8
2022	51.3
2023	25.4
2024 and thereafter	1.9
Total lease payments	$	321.2

Lessee Information

Operating Leases. Future minimum lease commitments under the Company's operating leases as of December 31, 2018, are as follows (in millions):


Fiscal Year	Amount
2019	$	15.1
2020	14.5
2021	12.7
2022	11.2
2023	11.0
2024 and thereafter	30.9
Total lease payments	$	95.4

Leases

LEASES

Lessor Information related to Intuitive System Leasing

Sales-type Leases. Lease receivables relating to sales-type lease arrangements are presented on the Consolidated Balance Sheets as follows (in millions):


	December 31,
	2019		2018
Gross lease receivables	$	191.9	$	150.4
Unearned income	(10.1)		(6.3)
Allowance for credit loss	(1.2)		(1.0)
Net investment in sales-type leases	$	180.6	$	143.1
Reported as:
Prepaids and other current assets	$	63.1	$	51.2
Intangible and other assets, net	117.5		91.9
Total, net	$	180.6	$	143.1

Contractual maturities of gross lease receivables as of December 31, 2019, are as follows (in millions):


Fiscal Year	Amount

2020	$	63.5
2021	52.9
2022	36.2
2023	22.1
2024	15.4
2025 and thereafter	1.8
Total	$	191.9


Fiscal Year	Amount

2020	$	146.5
2021	134.2
2022	116.0
2023	86.6
2024	40.6
2025 and thereafter	10.8
Total	$	534.7

Contingent rental revenue relating to operating lease arrangements was not material for the years ended December 31, 2019, 2018, and 2017.

Lessee Information

Supplemental cash flow information for the year ended December 31, 2019, related to operating leases was as follows (in millions):


	Amount
Cash paid for leases that were included within operating cash outflows	$	18.8
Right-of-use assets recognized related to new lease obligations	$	21.5

Supplemental balance sheet information, as of December 31, 2019, related to operating leases was as follows (in millions, except lease term and discount rate):


Reported as:	Amount
Intangible and other assets, net (Right-of-use assets)	$	74.4
Other accrued liabilities	$	7.7
Other long-term liabilities	68.7
Total lease liabilities	$	76.4
Weighted average remaining lease term	6.1 years
Weighted average discount rate	3.4		%

As of December 31, 2019, the future payments related to the Company's operating lease liabilities are scheduled as follows (in millions):


Fiscal Year	Amount
2020	$	9.6
2021	19.7
2022	14.7
2023	12.8
2024	8.4
2025 and thereafter	22.4
Total lease payments	$	87.6
Less imputed interest	(11.2)
Total operating lease liabilities	$	76.4

ASC 840 Disclosures

The Company elected the alternative modified transition method and is required to present previously disclosed information under the prior accounting standards for leases.

Lessor Information

Sales-type Leases. Contractual maturities of gross lease receivables as of December 31, 2018, are as follows (in millions):


Fiscal Year	Amount
2019	$	50.8
2020	46.5
2021	29.7
2022	14.9
2023	7.5
2024 and thereafter	1.0
Total lease payments	$	150.4


Fiscal Year	Amount
2019	$	88.0
2020	85.8
2021	68.8
2022	51.3
2023	25.4
2024 and thereafter	1.9
Total lease payments	$	321.2

Lessee Information

Operating Leases. Future minimum lease commitments under the Company's operating leases as of December 31, 2018, are as follows (in millions):


Fiscal Year	Amount
2019	$	15.1
2020	14.5
2021	12.7
2022	11.2
2023	11.0
2024 and thereafter	30.9
Total lease payments	$	95.4

Leases

LEASES

Lessor Information related to Intuitive System Leasing

Sales-type Leases. Lease receivables relating to sales-type lease arrangements are presented on the Consolidated Balance Sheets as follows (in millions):


	December 31,
	2019		2018
Gross lease receivables	$	191.9	$	150.4
Unearned income	(10.1)		(6.3)
Allowance for credit loss	(1.2)		(1.0)
Net investment in sales-type leases	$	180.6	$	143.1
Reported as:
Prepaids and other current assets	$	63.1	$	51.2
Intangible and other assets, net	117.5		91.9
Total, net	$	180.6	$	143.1

Contractual maturities of gross lease receivables as of December 31, 2019, are as follows (in millions):


Fiscal Year	Amount

2020	$	63.5
2021	52.9
2022	36.2
2023	22.1
2024	15.4
2025 and thereafter	1.8
Total	$	191.9


Fiscal Year	Amount

2020	$	146.5
2021	134.2
2022	116.0
2023	86.6
2024	40.6
2025 and thereafter	10.8
Total	$	534.7

Contingent rental revenue relating to operating lease arrangements was not material for the years ended December 31, 2019, 2018, and 2017.

Lessee Information

Supplemental cash flow information for the year ended December 31, 2019, related to operating leases was as follows (in millions):


	Amount
Cash paid for leases that were included within operating cash outflows	$	18.8
Right-of-use assets recognized related to new lease obligations	$	21.5

Supplemental balance sheet information, as of December 31, 2019, related to operating leases was as follows (in millions, except lease term and discount rate):


Reported as:	Amount
Intangible and other assets, net (Right-of-use assets)	$	74.4
Other accrued liabilities	$	7.7
Other long-term liabilities	68.7
Total lease liabilities	$	76.4
Weighted average remaining lease term	6.1 years
Weighted average discount rate	3.4		%

As of December 31, 2019, the future payments related to the Company's operating lease liabilities are scheduled as follows (in millions):


Fiscal Year	Amount
2020	$	9.6
2021	19.7
2022	14.7
2023	12.8
2024	8.4
2025 and thereafter	22.4
Total lease payments	$	87.6
Less imputed interest	(11.2)
Total operating lease liabilities	$	76.4

ASC 840 Disclosures

The Company elected the alternative modified transition method and is required to present previously disclosed information under the prior accounting standards for leases.

Lessor Information

Sales-type Leases. Contractual maturities of gross lease receivables as of December 31, 2018, are as follows (in millions):


Fiscal Year	Amount
2019	$	50.8
2020	46.5
2021	29.7
2022	14.9
2023	7.5
2024 and thereafter	1.0
Total lease payments	$	150.4


Fiscal Year	Amount
2019	$	88.0
2020	85.8
2021	68.8
2022	51.3
2023	25.4
2024 and thereafter	1.9
Total lease payments	$	321.2

Lessee Information

Operating Leases. Future minimum lease commitments under the Company's operating leases as of December 31, 2018, are as follows (in millions):


Fiscal Year	Amount
2019	$	15.1
2020	14.5
2021	12.7
2022	11.2
2023	11.0
2024 and thereafter	30.9
Total lease payments	$	95.4

Selected Quarterly Data - Schedule Of Selected Quarterly Data (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Selected Quarterly Financial Information [Abstract]
Total revenue	$ 1,277.7	$ 1,128.2	$ 1,098.9	$ 973.7	$ 1,046.5	$ 920.9	$ 909.3	$ 847.5	$ 4,478.5	$ 3,724.2	$ 3,138.2
Gross profit	896.0	785.6	759.0	669.6	735.7	642.3	632.3	593.8	3,110.2	2,604.1	2,202.0
Net income	$ 357.7	$ 396.8	$ 318.3	$ 306.5	$ 292.5	$ 292.5	$ 255.3	$ 287.6	$ 1,379.3	$ 1,127.9	$ 670.9
Basic net income per share (usd per share)	$ 3.09	$ 3.44	$ 2.76	$ 2.67	$ 2.56	$ 2.57	$ 2.25	$ 2.55	$ 11.95	$ 9.92	$ 6.01
Diluted net income per share (usd per share)	$ 2.99	$ 3.33	$ 2.67	$ 2.56	$ 2.45	$ 2.45	$ 2.15	$ 2.44	$ 11.54	$ 9.49	$ 5.77
Excess tax benefits related to share-based compensation arrangements	$ 33.7	$ 28.8	$ 11.3	$ 72.7	$ 15.8	$ 24.1	$ 21.6	$ 54.7	$ 146.5	$ 116.2	$ 102.8
One-time tax benefit related to the enactment of Swiss tax reform	0.0	51.3	0.0	0.0	2.5	4.6	0.0	0.0
Includes acquisition-related benefits (charges)	(3.1)	3.0	(4.1)	(3.0)
Includes pre-tax litigation (charges)					0.0	1.8	(42.5)	(4.5)
Includes charitable foundation contribution expense	$ (5.0)	$ 0.0	$ 0.0	$ 0.0	$ (25.2)	$ 0.0	$ 0.0	$ 0.0

Income Taxes - Schedule Of Income Tax Difference From Statutory Rate (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended								12 Months Ended
	Aug. 31, 2019	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Federal tax at statutory rate										$ 315.5	$ 268.7	$ 386.7
State taxes, net of federal benefits										29.7	20.8	16.0
Foreign rate differential										(56.2)	(44.7)	(115.7)
U.S. tax on foreign earnings										55.0	43.7	8.4
Research and development credit										(32.7)	(25.2)	(15.3)
Share-based compensation not benefited										13.5	9.9	10.8
Domestic production activities deduction										0.0	0.0	(7.9)
Reversal of unrecognized tax benefits										(8.4)	(5.2)	(62.4)
Tax Cuts and Jobs Act impact										0.0	0.5	317.8
Excess tax benefits related to share-based compensation arrangements		$ (33.7)	$ (28.8)	$ (11.3)	$ (72.7)	$ (15.8)	$ (24.1)	$ (21.6)	$ (54.7)	(146.5)	(116.2)	(102.8)
Deferred tax remeasurement due to Swiss Tax Reform	$ (51.3)									(51.3)	0.0	0.0
Other										1.8	2.2	(1.7)
Total income tax expense										$ 120.4	$ 154.5	$ 433.9

Selected Quarterly Data

12 Months Ended

Dec. 31, 2019

Selected Quarterly Financial Information [Abstract]

Selected Quarterly Data


	Three Months Ended
	December 31, 2019		September 30, 2019		June 30, 2019		March 31, 2019
Revenue	$	1,277.7	$	1,128.2	$	1,098.9	$	973.7
Gross profit	$	896.0	$	785.6	$	759.0	$	669.6
Net income attributable to Intuitive Surgical, Inc. ^(1)(2)(3)	$	357.7	$	396.8	$	318.3	$	306.5
Net income attributable to Intuitive Surgical, Inc. per share:
Basic	$	3.09	$	3.44	$	2.76	$	2.67
Diluted	$	2.99	$	3.33	$	2.67	$	2.56

(1) Includes discrete tax benefits as follows:
Excess tax benefits related to share-based compensation arrangements	$	33.7	$	28.8	$	11.3	$	72.7
One-time tax benefit related to the enactment of Swiss tax reform	$	—	$	51.3	$	—	$	—
(2) Includes acquisition-related benefits (charges)	$	(3.1)	$	3.0	$	(4.1)	$	(3.0)
(3) Includes charitable foundation contribution expense	$	(5.0)	$	—	$	—	$	—

	Three Months Ended
	December 31, 2018		September 30, 2018		June 30, 2018		March 31, 2018
Revenue	$	1,046.5	$	920.9	$	909.3	$	847.5
Gross profit	$	735.7	$	642.3	$	632.3	$	593.8
Net income attributable to Intuitive Surgical, Inc. ^(1)(2)(3)	$	292.5	$	292.5	$	255.3	$	287.6
Net income attributable to Intuitive Surgical, Inc. per share:
Basic	$	2.56	$	2.57	$	2.25	$	2.55
Diluted	$	2.45	$	2.45	$	2.15	$	2.44

(1) Includes discrete tax benefits as follows:
Excess tax benefits related to share-based compensation arrangements	$	15.8	$	24.1	$	21.6	$	54.7
Certain one-time tax benefits	$	2.5	$	4.6	$	—	$	—
(2) Includes pre-tax litigation benefits (charges)	$	—	$	1.8	$	(42.5)	$	(4.5)
(3) Includes charitable foundation contribution expense	$	(25.2)	$	—	$	—	$	—

Intangible Assets

12 Months Ended

Dec. 31, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets

GOODWILL AND INTANGIBLE ASSETS

Acquisitions in 2019

Chindex

During the first quarter of 2019, the Company's majority-owned Joint Venture with Fosun Pharma acquired certain assets from Chindex and its affiliates, a subsidiary of Fosun Pharma, including distribution rights, customer relationships, and certain personnel on January 5, 2019, which collectively met the definition of a business. Chindex was the Company's distributor of da Vinci products and services in China. The transaction enhances the Company's ability to serve patients, surgeons, and hospitals in China.

The total purchase consideration of $66.0 million, as of the acquisition date, included a contingent consideration liability of $64.7 million and an upfront cash payment of $1.3 million. The amount and timing of the future contingent consideration payments are based upon the underlying performance of the business in 2019 and 2020. As of the acquisition date, the estimated total undiscounted contingent consideration was approximately $81 million. As of December 31, 2019, the estimated total undiscounted contingent consideration has decreased by approximately $6 million due to a change in the timing of the milestone achievements. The contingent consideration liability was measured at estimated fair value using a discounted cash flow model, which requires significant inputs not observable in the market and, thus, represents a Level 3 measurement. Key assumptions included (1) the probability and timing of milestone achievements based on projected future revenues through 2019 and 2020, and (2) the discount rate used to calculate the present value of the milestone payments. At each reporting period until the contingent consideration is settled, the Company remeasures the contingent consideration liability and records changes in fair value within selling, general and administrative expenses. For the year ended December 31, 2019, the contingent consideration liability changed due to payments of $16.5 million and net additional expenses of $7.2 million, primarily related to accretion due to the passage of time. Changes to the contingent consideration estimate can result from adjustments to discount rates, accretion due to the passage of time, or change in estimates in the performance of the business. The assumptions related to determining the fair value of contingent consideration include a significant amount of judgment, and any changes in the underlying estimates could have a material impact on the amount of contingent consideration adjustment recorded in any given period.

The Company recorded $1.7 million of net tangible assets, $58.6 million of intangible assets, and $5.7 million of residual goodwill. Intangible assets included distribution rights of $48.2 million and customer relationships of $10.4 million, which are being amortized over a weighted-average period of 2.9 years. Key assumptions included (1) the amount and timing of projected

future cash flows, and (2) the discount rate used to determine the present value of these cash flows. The goodwill is not amortizable for income tax purposes. The allocation of purchase consideration was completed in the third quarter of 2019. There were no adjustments to the provisional amounts in the measurement period.

Schölly

During the third quarter of 2019, the Company acquired certain assets and operations from Schölly Fiberoptic GmbH ("Schölly"), including manufacturing process technology, a non-compete agreement, certain personnel, and net tangible assets on August 31, 2019, which collectively met the definition of a business. The Company believes that the transaction strengthens the Company's supply chain and manufacturing capacity for imaging products used in the Company's da Vinci systems. The total purchase consideration of $101.4 million consists of an initial cash payment of $34.4 million and deferred cash payments totaling approximately $67.0 million, of which $37.3 million continues to be deferred as of December 31, 2019. The timing of the future payments is based upon achieving certain integration steps, which occur during 2020 and are expected to be completed around the end of 2020.

The Company preliminarily recorded $10.7 million of net tangible assets, which included $6.7 million of inventory and $1.4 million of cash, $31.0 million of intangible assets, and $59.7 million of residual goodwill. The balances include the net impact of adjustments to the preliminary allocation of the purchase price within the one year measurement period, which increased intangible assets and goodwill by $0.5 million and $0.4 million, respectively, during the fourth quarter of 2019. There was no significant impact to the Consolidated Statements of Income as result of these adjustments. Intangible assets included manufacturing process technology of $28.0 million and non-compete provisions of $3.0 million, which are being amortized over a weighted-average period of 6.6 years. Key assumptions included (1) the amount and timing of projected future cash flows, and (2) the discount rate used to determine the present value of these cash flows. The allocation of purchase consideration is considered preliminary with provisional amounts primarily related to working capital. Goodwill primarily consists of the manufacturing and other synergies of the combined operations and the value of the assembled workforce. The majority of goodwill is not deductible for income tax purposes.

In 2019, the Company has included the results of the acquired businesses, since their acquisition dates, in its Consolidated Financial Statements, and the revenues and earnings were not material in the year. Pro forma results of operations related to the acquisitions have not been presented, because the operating results of the acquired businesses are not considered material to the Consolidated Financial Statements.

Acquisitions in 2018

During the second quarter of 2018, the Company terminated its India distribution relationship with Vattikuti Technologies Pvt. Ltd. and acquired certain assets related to that distribution business on May 25, 2018, which collectively met the definition of a business. The transaction enhances the Company’s ability to serve patients, surgeons, and hospitals in India. After the net impact of measurement-period adjustments of $2.5 million, the purchase consideration consisted of $36.2 million in cash and the Company recorded $4.1 million of net tangible assets, $24.2 million of intangible assets, and $7.3 million of residual goodwill. Intangible assets included reacquired distribution rights, customer relationships, and a non-compete agreement, which are being amortized over a weighted average period of 4.3 years.

During the third quarter of 2018, the Company acquired intellectual property, exclusive field of use rights, and certain key employees from InTouch Technologies, Inc. on August 17, 2018, which collectively met the definition of a business. The transaction enhances the Company’s network capabilities in using real-time data to support surgeons. The total purchase consideration of $38.7 million, as of the acquisition date, consisted of an initial cash payment of $22.0 million and subsequent cash payments totaling approximately $16.7 million. The Company recorded $13.3 million of intangible assets and $25.4 million of residual goodwill. Intangible assets included developed technology and a non-compete agreement, which are being amortized over a weighted average period of 5.7 years. The goodwill will be amortized for income tax purposes.

During the fourth quarter of 2018, the Company acquired its Taiwan distributor, Unison Surgicals Company, on December 11, 2018, which met the definition of a business. The transaction enhances the Company’s ability to serve patients, surgeons, and hospitals in Taiwan. The purchase consideration consisted of $35.4 million in cash. The Company recorded $13.1 million of net tangible assets, which included $7.6 million of cash, $17.3 million of intangible assets, and $5.0 million of residual goodwill. Intangible assets included customer relationships and non-compete agreements, which are being amortized over a weighted average period of 6.6 years.

In 2018, the Company has included the results of the acquired businesses, since their acquisition dates, in its Consolidated Financial Statements, and the revenues and earnings were not material in the year. Pro forma results of operations related to the acquisitions have not been presented, because the operating results of the acquired businesses are not material to the Consolidated Financial Statements.

Goodwill

The following table summarizes the changes in the carrying amount of goodwill (in millions):


	Amount
Balance at December 31, 2017	$	201.1
Acquisition activity	40.2
Translation and other	(0.7)
Balance at December 31, 2018	240.6
Acquisition activity	65.4
Translation and other	1.2
Balance at December 31, 2019	$	307.2

The Company completed its annual goodwill impairment test and determined that no impairment existed. As of December 31, 2019, there has been no impairment of goodwill.

Intangible Assets

The following table summarizes the components of gross intangible asset, accumulated amortization, and net intangible asset balances as of December 31, 2019, and 2018 (in millions):


	December 31, 2019										December 31, 2018
	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount
Patents and developed technology	$	186.7	$	(149.0)	$	37.7	$	158.7	$	(144.7)	$	14.0
Distribution rights and others	91.3		(44.9)		46.4		40.2		(12.9)		27.3
Customer relationships	57.7		(29.7)		28.0		48.5		(23.1)		25.4
Total intangible assets	$	335.7	$	(223.6)	$	112.1	$	247.4	$	(180.7)	$	66.7

Amortization expense related to intangible assets was $43.0 million, $14.2 million, and $12.9 million for the years ended December 31, 2019, 2018, and 2017, respectively.

The estimated future amortization expense related to intangible assets as of December 31, 2019, is as follows (in millions):


Fiscal Year	Amount
2020	$	46.1
2021	18.7
2022	16.0
2023	11.5
2024	9.4
2025 and thereafter	10.4
Total	$	112.1

Share-Based Compensation - Share-Based Compensation Expense (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense before income taxes	$ 337.9	$ 262.6	$ 209.9
Income tax effect	70.2	54.3	49.2
Share-based compensation expense after income taxes	267.7	208.3	160.7
Total cost of sales
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense before income taxes	67.0	53.2	42.1
Total cost of sales \| Cost of sales—products
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense before income taxes	46.6	36.4	28.1
Total cost of sales \| Cost of sales—services
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense before income taxes	20.4	16.8	14.0
Selling, general and administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense before income taxes	169.5	133.2	111.8
Research and development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense before income taxes	$ 101.4	$ 76.2	$ 56.0

Leases - Lease Receivables (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Capital Leased Assets [Line Items]
Gross lease receivables	$ 191.9
Gross lease receivables		$ 150.4
Unearned income	(10.1)
Unearned income		(6.3)
Allowance for credit loss	(1.2)
Allowance for credit loss		(1.0)
Net investment in sales-type leases	180.6
Net investment in sales-type leases		143.1
Reported as:
Net investment in sales-type leases		143.1
Prepaid and other current assets
Capital Leased Assets [Line Items]
Net investment in sales-type leases	63.1
Reported as:
Prepaids and other current assets		51.2
Intangible and other assets, net
Capital Leased Assets [Line Items]
Net investment in sales-type leases	$ 117.5
Reported as:
Intangible and other assets, net		$ 91.9

Financial Instruments - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Net unrealized gains/(losses) on investments	$ 20.4	$ (9.8)
Prepaid and other current assets
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Restricted Cash and Cash Equivalents		$ 36.5

Selected Quarterly Data (Tables)

12 Months Ended

Dec. 31, 2019

Selected Quarterly Financial Information [Abstract]

Schedule Of Selected Quarterly Data


	Three Months Ended
	December 31, 2019		September 30, 2019		June 30, 2019		March 31, 2019
Revenue	$	1,277.7	$	1,128.2	$	1,098.9	$	973.7
Gross profit	$	896.0	$	785.6	$	759.0	$	669.6
Net income attributable to Intuitive Surgical, Inc. ^(1)(2)(3)	$	357.7	$	396.8	$	318.3	$	306.5
Net income attributable to Intuitive Surgical, Inc. per share:
Basic	$	3.09	$	3.44	$	2.76	$	2.67
Diluted	$	2.99	$	3.33	$	2.67	$	2.56

(1) Includes discrete tax benefits as follows:
Excess tax benefits related to share-based compensation arrangements	$	33.7	$	28.8	$	11.3	$	72.7
One-time tax benefit related to the enactment of Swiss tax reform	$	—	$	51.3	$	—	$	—
(2) Includes acquisition-related benefits (charges)	$	(3.1)	$	3.0	$	(4.1)	$	(3.0)
(3) Includes charitable foundation contribution expense	$	(5.0)	$	—	$	—	$	—

	Three Months Ended
	December 31, 2018		September 30, 2018		June 30, 2018		March 31, 2018
Revenue	$	1,046.5	$	920.9	$	909.3	$	847.5
Gross profit	$	735.7	$	642.3	$	632.3	$	593.8
Net income attributable to Intuitive Surgical, Inc. ^(1)(2)(3)	$	292.5	$	292.5	$	255.3	$	287.6
Net income attributable to Intuitive Surgical, Inc. per share:
Basic	$	2.56	$	2.57	$	2.25	$	2.55
Diluted	$	2.45	$	2.45	$	2.15	$	2.44

(1) Includes discrete tax benefits as follows:
Excess tax benefits related to share-based compensation arrangements	$	15.8	$	24.1	$	21.6	$	54.7
Certain one-time tax benefits	$	2.5	$	4.6	$	—	$	—
(2) Includes pre-tax litigation benefits (charges)	$	—	$	1.8	$	(42.5)	$	(4.5)
(3) Includes charitable foundation contribution expense	$	(25.2)	$	—	$	—	$	—

Income Taxes - Schedule Of Gross Unrecognized Income Tax Benefits (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Reconciliation of Unrecognized Tax Benefits [Roll Forward]
Beginning balance	$ 78.8	$ 65.4	$ 106.0
Increases related to tax positions taken during the current year	26.5	22.5	21.1
Increases related to tax positions taken during a prior year	1.2	0.0	0.0
Decreases related to tax positions taken during a prior year	0.0	(0.9)	(46.5)
Decreases related to settlements with tax authorities	(3.8)	0.0	(0.5)
Decreases related to expiration of statute of limitations	(6.0)	(8.2)	(14.7)
Ending balance	$ 96.7	$ 78.8	$ 65.4

Financial Instruments - Derivative Instruments Used to Hedge against Balance Sheet Foreign Currency Exposures (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange gains (losses) related to balance sheet re-measurement	$ (1.5)	$ (2.6)	$ 9.7
Foreign Exchange Forward \| Other income \| Derivatives Not Designated as Hedging Instruments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Recognized gains (losses) in interest and other income, net	$ 6.4	$ 8.7	$ (9.2)

Cover Page - USD ($) $ in Billions	12 Months Ended
Cover Page - USD ($) $ in Billions	Dec. 31, 2019	Jan. 17, 2020	Jun. 30, 2019
Cover page.
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2019
Document Transition Report	false
Entity File Number	000-30713
Entity Registrant Name	Intuitive Surgical, Inc.
State or Other Jurisdiction of Incorporation or Organization	DE
I.R.S. Employer Identification No.	77-0416458
Entity Address, Address Line One	1020 Kifer Road
Entity Address, City or Town	Sunnyvale
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94086
City Area Code	(408)
Local Phone Number	523-2100
Title of Each Class	Common Stock, par value $0.001 per share
Trading Symbol	ISRG
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 59.9
Entity Common Stock, Shares Outstanding		115,984,044
Documents Incorporated by Reference	Part III incorporates information by reference to the definitive proxy statement for the Company’s Annual Meeting of Stockholders to be held on or about April 23, 2020, to be filed within 120 days of the registrant’s fiscal year ended December 31, 2019.
Entity Central Index Key	0001035267
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Amendment Flag	false

Share-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2019

Share-based Payment Arrangement [Abstract]

Summary Of Stock Option Activity Under All Stock Plans

Option activity during fiscal 2019 under all the stock plans was as follows (in millions, except per share amounts):


	Stock Options Outstanding
	Number Outstanding	Weighted Average Exercise Price Per Share
Balance at December 31, 2018	6.2	$	200.79

Options granted	0.6	$	523.30
Options exercised	(1.3)	$	159.46
Options forfeited/expired	(0.1)	$	381.82
Balance at December 31, 2019	5.4	$	246.64

Summary Of Significant Ranges Of Outstanding And Exercisable Options

The following table summarizes significant ranges of outstanding and exercisable options as of December 31, 2019 (number of shares and aggregate intrinsic value in millions):


	Options Outstanding										Options Exercisable
Range of Exercise Prices	Number of Shares	Weighted Average Remaining Contractual Life	Weighted Average Exercise Price Per Share		Aggregate Intrinsic Value (1)		Number of Shares	Weighted Average Remaining Contractual Life	Weighted Average Exercise Price Per Share		Aggregate Intrinsic Value (1)
$86.88-$148.03	1.1	2.8	$	127.46			1.1		$	127.46
$150.50-$172.44	1.4	3.6	$	166.28			1.4		$	166.29
$172.76-$231.00	1.2	5.1	$	194.42			1.2		$	193.89
$231.11-$505.36	1.1	8.1	$	376.53			0.5		$	334.67
$508.19-$585.57	0.6	9.0	$	536.41			0.1		$	531.66
Total	5.4	5.3	$	246.64	$	1,844.4	4.3	4.4	$	195.76	$	1,702.4

(1)The aggregate intrinsic value represents the total pre-tax intrinsic value, based on the Company’s closing stock price of $591.15 at December 31, 2019, which would have been received by the option holders had all in-the-money option holders exercised their options as of that date.

Summary of RSU Activity

RSU activity for the year ended December 31, 2019, was as follows (in millions, except per share amounts):


	Shares	Weighted Average Grant Date Fair Value
Unvested balance at December 31, 2018	2.0	$	295.70
Granted	0.8	541.36
Vested	(0.8)	258.87
Forfeited	(0.1)	382.52
Unvested balance at December 31, 2019	1.9	410.09

Summary Of Share-Based Compensation Expense

The following table summarizes share-based compensation expense (in millions):


	Years Ended December 31,
	2019		2018		2017
Cost of sales—products	$	46.6	$	36.4	$	28.1
Cost of sales—services	20.4		16.8		14.0
Total cost of sales	67.0		53.2		42.1
Selling, general and administrative	169.5		133.2		111.8
Research and development	101.4		76.2		56.0
Share-based compensation expense before income taxes	337.9		262.6		209.9
Income tax effect	70.2		54.3		49.2
Share-based compensation expense after income taxes	$	267.7	$	208.3	$	160.7

Schedule Of Estimated Fair Values Of The Option Using Black-Scholes Option Pricing Model, Weighted Average Assumptions and Fair Value of RSUs

The weighted-average estimated fair values of stock options, the rights to acquire stock under the ESPP, and RSUs, as well as the weighted average assumptions used in calculating the fair values of stock options and rights to acquire stock under the ESPP that were granted during the years ended December 31, 2019, 2018, and 2017, were as follows:


	Years Ended December 31,
STOCK OPTION PLANS	2019			2018			2017
Risk-free interest rate	2.0		%	2.7		%	1.8		%
Expected term (years)	4.1			4.3			4.1
Volatility	30		%	33		%	25		%
Fair value at grant date	$	142.53		$	146.30		$	67.03

EMPLOYEE STOCK PURCHASE PLAN
Risk-free interest rate	2.1		%	2.1		%	1.2		%
Expected term (years)	1.2			1.3			1.2
Volatility	29		%	32		%	28		%
Fair value at grant date	$	148.99		$	135.84		$	79.77
RESTRICTED STOCK UNITS
Fair value at grant date	$	541.36		$	431.11		$	249.34

Employee Benefit Plans	12 Months Ended
Employee Benefit Plans	Dec. 31, 2019
Retirement Benefits [Abstract]
Employee Benefit Plans	EMPLOYEE BENEFIT PLANSThe Company sponsors various retirement plans for its eligible U.S. and non-U.S. employees. For employees in the U.S., the Company maintains the Intuitive Surgical, Inc. 401(k) Plan (the “Plan”). As allowed under Section 401(k) of the Internal Revenue Code, the Plan provides tax-deferred salary contributions for eligible U.S. employees. The Plan allows employees to contribute up to 100% of their annual compensation to the Plan on a pre-tax and after-tax basis. Employee contributions are limited to a maximum annual amount as set periodically by the Internal Revenue Code. The Company matches 200% of employee contributions up to $1,500 per calendar year per person. All matching employer contributions vest immediately.

Share-Based Compensation - Schedule Of Estimated Fair Value Of Option Using Black-Scholes Option Pricing Model, Weighted Average Assumptions (Details) - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
STOCK OPTION PLANS
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	2.00%	2.70%	1.80%
Expected term (years)	4 years 1 month 6 days	4 years 3 months 18 days	4 years 1 month 6 days
Volatility (percent)	30.00%	33.00%	25.00%
Weighted average fair value at grant date (usd per share)	$ 142.53	$ 146.30	$ 67.03
EMPLOYEE STOCK PURCHASE PLAN
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	2.10%	2.10%	1.20%
Expected term (years)	1 year 2 months 12 days	1 year 3 months 18 days	1 year 2 months 12 days
Volatility (percent)	29.00%	32.00%	28.00%
Weighted average fair value at grant date (usd per share)	$ 148.99	$ 135.84	$ 79.77
RESTRICTED STOCK UNITS
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value at grant date (usd per share)	$ 541.36	$ 431.11	$ 249.34

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Current assets:
Cash and Cash Equivalents	$ 1,167.6	$ 857.9
Short-term investments	2,054.1	2,205.2
Accounts receivable, net of allowances of $8.3 and $8.2 as of December 31, 2019, and 2018, respectively	645.2	682.3
Inventory	595.5	409.0
Prepaids and other current assets	200.2	178.8
Total current assets	4,662.6	4,333.2
Property, plant, and equipment, net	1,272.9	812.0
Long-term investments	2,623.5	1,771.3
Deferred tax assets	425.6	428.6
Intangible and other assets, net	441.4	261.0
Goodwill	307.2	240.6
Total assets	9,733.2	7,846.7
Current liabilities:
Accounts payable	123.5	100.7
Accrued compensation and employee benefits	251.6	193.8
Deferred revenue	337.8	294.3
Other accrued liabilities	317.3	231.8
Total current liabilities	1,030.2	820.6
Other long-term liabilities	418.3	338.6
Total liabilities	1,448.5	1,159.2
Commitments and contingencies (Note 8)
Stockholders’ equity:
Preferred stock, 2.5 shares authorized, $0.001 par value, issuable in series; no shares issued and outstanding as of December 31, 2019, and 2018	0.0	0.0
Common stock, 300.0 shares authorized, $0.001 par value, 116.0 shares and 114.5 shares issued and outstanding as of December 31, 2019, and 2018, respectively	0.1	0.1
Additional paid-in capital	5,756.8	5,170.3
Retained earnings	2,494.5	1,521.7
Accumulated other comprehensive income/(loss)	12.4	(13.3)
Total Intuitive Surgical, Inc. stockholders’ equity	8,263.8	6,678.8
Noncontrolling interest in joint venture	20.9	8.7
Total stockholders’ equity	8,284.7	6,687.5
Total liabilities and stockholders’ equity	$ 9,733.2	$ 7,846.7

Consolidated Statements Of Stockholders' Equity - USD ($)
shares in Millions, $ in Millions

Total

Common Stock

Additional Paid-In Capital

Retained Earnings

Accumulated Other Comprehensive Income/(Loss)

Total Intuitive Surgical, Inc. Stockholders’ Equity

Noncontrolling Interest in Joint Venture

Beginning balances (shares) at Dec. 31, 2016

38.8

Beginning balance at Dec. 31, 2016

$ 5,820.5

$ 0.0

$ 4,211.8

$ 1,617.6

$ (8.9)

$ 5,820.5

$ 0.0

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Three-for-one stock split (shares)

77.6

Three-for-one stock split

0.0

$ 0.1

(0.1)

Issuance of common stock through employee stock plans (shares)

3.4

Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture

415.5

Shares withheld related to net share settlement of equity awards (shares)

(0.2)

Shares withheld related to net share settlement of equity awards

(56.6)

(5.1)

(51.5)

(56.6)

Share-based compensation expense related to employee stock plans

209.1

Repurchase and retirement of common stock (shares)

(7.3)

Repurchase and retirement of common stock

(2,274.0)

(152.0)

(2,122.0)

(2,274.0)

Net income attributable to Intuitive Surgical, Inc.

670.9

Other comprehensive loss

(6.6)

Other comprehensive income (loss)

(6.6)

Capital contribution from noncontrolling interest

2.0

Net loss attributable to noncontrolling interest in joint venture

(0.4)

Ending balances (shares) at Dec. 31, 2017

112.3

Beginning balance at Dec. 31, 2017

4,780.4

$ 0.1

4,679.2

115.0

(15.5)

4,778.8

1.6

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Adoption of new accounting standard

^[1]

390.8

392.1

(1.3)

390.8

Issuance of common stock through employee stock plans (shares)

2.5

Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture

236.6

Shares withheld related to net share settlement of equity awards (shares)

(0.3)

Shares withheld related to net share settlement of equity awards

(120.0)

(6.7)

(113.3)

(120.0)

Share-based compensation expense related to employee stock plans

261.2

Net income attributable to Intuitive Surgical, Inc.

1,127.9

Other comprehensive loss

2.2

Other comprehensive income

3.5

Capital contribution from noncontrolling interest

10.0

Net loss attributable to noncontrolling interest in joint venture

$ (2.9)

(2.9)

Ending balances (shares) at Dec. 31, 2018

114.5

Beginning balance at Dec. 31, 2018

$ 6,687.5

$ 0.1

5,170.3

1,521.7

(13.3)

6,678.8

8.7

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Issuance of common stock through employee stock plans (shares)

2.4

Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture

272.8

Shares withheld related to net share settlement of equity awards (shares)

(0.3)

Shares withheld related to net share settlement of equity awards

(159.1)

(7.6)

(151.5)

(159.1)

Share-based compensation expense related to employee stock plans

335.8

Repurchase and retirement of common stock (shares)

(0.6)

Repurchase and retirement of common stock

(269.5)

(14.5)

(255.0)

(269.5)

Net income attributable to Intuitive Surgical, Inc.

1,379.3

Other comprehensive loss

25.7

Other comprehensive income (loss)

25.4

25.7

(0.3)

Capital contribution from noncontrolling interest

10.0

Net loss attributable to noncontrolling interest in joint venture

$ 2.5

2.5

Ending balances (shares) at Dec. 31, 2019

116.0

Beginning balance at Dec. 31, 2019

$ 8,284.7

$ 0.1

$ 5,756.8

$ 2,494.5

$ 12.4

$ 8,263.8

$ 20.9

[1]

(1) Represents the adjustments related to the adoptions of Accounting Standards Update ("ASU") 2016-16, Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other than Inventory, and ASU 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income.

Financial Instruments - Summary Of Contractual Maturities Of Cash Equivalents And Available-For-Sale Investments (Details) $ in Millions	Dec. 31, 2019 USD ($)
Amortized Cost
Mature in less than one year	$ 2,082.4
Mature in one to five years	2,595.8
Total	4,678.2
Fair Value
Mature in less than one year	2,087.7
Mature in one to five years	2,617.6
Total	$ 4,705.3

Financial Instruments (Tables)

12 Months Ended

Dec. 31, 2019

Fair Value Disclosures [Abstract]

Summary of Cash and Available-For-Sale Securities

The following tables summarize the Company’s cash and available-for-sale marketable securities’ amortized cost, gross unrealized gains, gross unrealized losses, and fair value by significant investment category reported as cash and cash equivalents or short-term or long-term investments as of December 31, 2019, and 2018 (in millions):


									Reported as:
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value		Cash and Cash Equivalents		Short-term Investments		Long-term Investments
December 31, 2019
Cash	$	413.1	$	—	$	—	$	413.1	$	413.1	$	—	$	—
Level 1:
Money market funds	726.8		—		—		726.8		726.8		—		—
U.S. treasuries	1,935.8		9.7		(0.4)		1,945.1		—		890.8		1,054.3
Subtotal	2,662.6		9.7		(0.4)		2,671.9		726.8		890.8		1,054.3
Level 2:
Commercial paper	165.1		—		—		165.1		25.5		139.6		—
Corporate securities	2,096.1		16.8		(0.2)		2,112.7		—		798.5		1,314.2
U.S. government agencies	418.3		1.1		(0.2)		419.2		—		209.6		209.6
Non-U.S. government securities	4.5		—		—		4.5		—		4.5		—
Municipal securities	58.4		0.3		—		58.7		2.2		11.1		45.4
Subtotal	2,742.4		18.2		(0.4)		2,760.2		27.7		1,163.3		1,569.2



Total assets measured at fair value	$	5,818.1	$	27.9	$	(0.8)	$	5,845.2	$	1,167.6	$	2,054.1	$	2,623.5


									Reported as:
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value		Cash and Cash Equivalents		Short-term Investments		Long-term Investments
December 31, 2018
Cash	$	269.4	$	—	$	—	$	269.4	$	269.4	$	—	$	—
Level 1:
Money market funds	569.1		—		—		569.1		569.1		—		—
U.S. treasuries	1,477.8		1.7		(5.3)		1,474.2		10.0		897.8		566.4
Subtotal	2,046.9		1.7		(5.3)		2,043.3		579.1		897.8		566.4
Level 2:
Commercial paper	110.7		—		—		110.7		1.4		109.3		—
Corporate securities	1,607.8		1.3		(4.8)		1,604.3		8.0		724.5		871.8
U.S. government agencies	791.8		0.3		(3.8)		788.3		—		468.9		319.4

Municipal securities	18.4		—		—		18.4		—		4.7		13.7
Subtotal	2,528.7		1.6		(8.6)		2,521.7		9.4		1,307.4		1,204.9



Total assets measured at fair value	$	4,845.0	$	3.3	$	(13.9)	$	4,834.4	$	857.9	$	2,205.2	$	1,771.3

Summary Of Contractual Maturities Of Cash Equivalents And Available-For-Sale Investments

The following table summarizes the contractual maturities of the Company’s cash equivalents and available-for-sale investments (excluding cash and money market funds) at December 31, 2019 (in millions):


	Amortized Cost		Fair Value
Mature in less than one year	$	2,082.4	$	2,087.7
Mature in one to five years	2,595.8		2,617.6

Total	$	4,678.2	$	4,705.3

Schedule Of Available-For-Sale Investments With Unrealized Losses

The following tables present the breakdown of the available-for-sale investments with unrealized losses at December 31, 2019, and 2018 (in millions):


	Unrealized losses less than 12 months						Unrealized losses 12 months or greater						Total
December 31, 2019	Fair Value		Unrealized Losses		Fair Value		Unrealized Losses		Fair Value		Unrealized Losses
Corporate securities	$	237.0	$	(0.2)	$	—	$	—	$	237.0	$	(0.2)
U.S. treasuries	236.5		(0.2)		87.5		(0.2)		324.0		(0.4)
U.S. government agencies	45.9		(0.1)		45.5		(0.1)		91.4		(0.2)
Total	$	519.4	$	(0.5)	$	133.0	$	(0.3)	$	652.4	$	(0.8)
December 31, 2018
Corporate securities	$	727.4	$	(1.7)	$	409.6	$	(3.1)	$	1,137.0	$	(4.8)
U.S. treasuries	478.7		(0.9)		592.8		(4.4)		1,071.5		(5.3)
U.S. government agencies	228.0		(0.2)		425.2		(3.6)		653.2		(3.8)
Total	$	1,434.1	$	(2.8)	$	1,427.6	$	(11.1)	$	2,861.7	$	(13.9)

Derivative Instruments Used to Hedge against Balance Sheet Foreign Currency Exposures

These derivative instruments are used to hedge against balance sheet foreign currency exposures. The related gains and losses were as follows (in millions):


	Years Ended December 31,
	2019		2018		2017
Recognized gains (losses) in interest and other income, net	$	6.4	$	8.7	$	(9.2)
Foreign exchange gains (losses) related to balance sheet re-measurement	$	(1.5)	$	(2.6)	$	9.7

Gross Notional Amounts for Outstanding Derivatives

Total gross notional amounts (in USD) for derivatives and the aggregate gross fair value outstanding at the end of each period were as follows (in millions):


	Derivatives Designated as Hedging Instruments						Derivatives Not Designated as Hedging Instruments
	December 31, 2019		December 31, 2018		December 31, 2019		December 31, 2018
Notional amounts:
Forward contracts	$	154.5	$	183.0	$	227.2	$	182.7
Gross fair value recorded in:
Prepaid and other current assets	$	1.3	$	3.1	$	2.2	$	4.1
Other accrued liabilities	$	0.5	$	0.9	$	0.7	$	1.1

Net Income Per Share (Tables)

12 Months Ended

Dec. 31, 2019

Earnings Per Share [Abstract]

Computation Of Basic And Diluted Net Income Per Share

The following table presents the computation of basic and diluted net income per share attributable to Intuitive Surgical, Inc. (in millions, except per share amounts):


	Years Ended December 31,
	2019		2018		2017
Numerator:
Net income attributable to Intuitive Surgical, Inc.	$	1,379.3	$	1,127.9	$	670.9
Denominator:
Weighted average shares outstanding used in basic calculation	115.4		113.7		111.7
Add: dilutive effect of potential common shares	4.1		5.1		4.6
Weighted average shares outstanding used in diluted calculation	119.5		118.8		116.3
Net income per share attributable to Intuitive Surgical, Inc.:
Basic	$	11.95	$	9.92	$	6.01
Diluted	$	11.54	$	9.49	$	5.77

Share-Based Compensation

12 Months Ended

Dec. 31, 2019

Share-based Payment Arrangement [Abstract]

Share-Based Compensation

SHARE-BASED COMPENSATION

Stock Plans

2010 Incentive Award Plan. In April 2010, the Company’s stockholders approved the 2010 Incentive Award Plan (“2010 Plan”). Under this plan, the Company issues nonqualified stock options (“NSOs”) and restricted stock units (“RSUs”) to employees and certain consultants. The 2010 Plan generally permits NSOs to be granted at no less than the fair market value of the common stock on the date of grant, with terms of 10 years from the date of grant. The 2010 Plan expires in 2029. In April 2019, the Company’s stockholders approved an amended and restated 2010 Plan to provide for an increase in the number of shares of common stock reserved for issuance from 24,450,000 to 28,450,000. As of December 31, 2019, approximately 5.9 million shares were reserved for future issuance under the 2010 Plan. A maximum of 2.6 million of these shares can be awarded as RSUs.

2009 Employment Commencement Incentive Plan. In October 2009, the Board adopted the 2009 Employment Commencement Incentive Plan (“New Hire Plan”). The New Hire Plan provides for the shares to be used exclusively for the grant of RSUs and NSOs to new employees (“New Hire Options”), who were not previously employees or non-employee directors of the Company. The Compensation Committee approves all equity awards under the New Hire Plan, which are granted to newly-hired employees once a month on the fifth business day of each month after their hire. Options are granted at an exercise price not less than the fair market value of the stock on the date of grant and have a term not to exceed 10 years.

In April 2015, the Board of Directors amended and restated the New Hire Plan to provide for an increase in the number of shares of common stock authorized for issuance pursuant to awards granted under the New Hire Plan from 3,465,000 to 4,365,000. The New Hire Plan expired in October 2019 and, therefore, there are no shares reserved for future issuance under the New Hire Plan. However, awards granted prior to the plan's expiration continue to remain outstanding until their original expiration date.

2000 Equity Incentive Plan. In March 2000, the Board adopted the 2000 Equity Incentive Plan (“2000 Plan”), which took effect upon the closing of the Company’s initial public offering. Under this plan, certain employees, consultants, and non-employee directors could be granted Incentive Stock Options (“ISOs”) and Nonstatutory Stock Options (“NSOs”) to purchase shares of the Company’s common stock. The 2000 Plan permitted ISOs to be granted at an exercise price not less than the fair value on the date of the grant and NSOs at an exercise price not less than 85% of the fair value on the date of grant. Options granted under the 2000 Plan generally expire 10 years from the date of grant and become exercisable upon grant subject to repurchase rights in favor of the Company until vested. The 2000 Plan expired in March 2010. However, options granted prior to the plan’s expiration continue to remain outstanding until their original expiration date.

Employee Option Vesting. The Company makes annual option grants on February 15 (or the next business day if the date is not a business day) and on August 15 (or the next business day if the date is not a business day). The February 15 grants vest 6/48 upon completion of 6 months of service and 1/48 per month thereafter. The August 15 stock option grants vest 7/48 at the end of one month and 1/48 per month thereafter through a 3.5-year vesting period.

New Hire Options generally vest 12/48 upon completion of one year of service and 1/48 per month thereafter. Option vesting terms are determined by the Board and, in the future, may vary from past practices.

2000 Non-Employee Directors’ Stock Option Plan. In March 2000, the Board of Directors adopted the 2000 Non-Employee Directors’ Stock Option Plan (the “Directors’ Plan”). In October 2009, the automatic evergreen increase provisions were eliminated so that no further automatic increases will be made to the number of shares reserved for issuance under the Directors’ Plan. In addition, the common stock authorized for issuance under the Directors’ Plan was reduced to 450,000. Options are granted at an exercise price not less than the fair market value of the stock on the date of grant and have a term not to exceed 10 years. Prior to 2016, initial stock option grants to new non-employee directors vested over a three-year period with 12/36 of the shares vesting after one year from the date of grant and 1/36 of the shares vesting monthly thereafter. Annual stock option grants vested one year from the date of the grant. Since 2016, new non-employee directors receive pro-rated stock option grants that vest on the same term as the annual stock option grants. As of December 31, 2019, approximately 0.1 million shares were reserved for future issuance under the Directors’ Plan. However, the Company no longer intends to issue grants from the Directors’ Plan in the future and instead plans to utilize the 2010 Plan to make grants to non-employee directors.

2000 Employee Stock Purchase Plan. In March 2000, the Board adopted the 2000 Employee Stock Purchase Plan (the “ESPP”). Employees are generally eligible to participate in the ESPP if they are customarily employed by the Company for more than 20 hours per week and more than 5 months in a calendar year and are not 5% stockholders of the Company. Under the ESPP, eligible employees may select a rate of payroll deduction up to 15% of their eligible compensation subject to certain maximum purchase limitations. The duration for each offering period is 24 months and is divided into four purchase periods of approximately six months in length. Offerings are concurrent. The purchase price of the shares under the offering is the lesser of 85% of the fair market value of the shares on the offering date or 85% of the fair market value of the shares on the purchase date. A two-year look-back feature in the ESPP causes the offering period to reset if the fair value of the Company’s common

stock on the first or last day of the purchase period is less than that on the original offering date. ESPP purchases by employees are settled with newly-issued common stock from the ESPP’s previously authorized and available pool of shares. In April 2017, the Company’s stockholders approved an amended and restated ESPP to provide for an increase in the number of shares of common stock reserved for issuance from 6,090,315 to 7,590,315.

The Company issued 0.2 million, 0.2 million, and 0.2 million shares under the ESPP, representing approximately $56.4 million, $46.8 million, and $38.3 million in employee contributions for the years ended December 31, 2019, 2018, and 2017, respectively. As of December 31, 2019, there were approximately 1.2 million shares reserved for future issuance under the ESPP.

Restricted Stock Units. Equity awards granted to employees and non-employee directors include a mix of stock options and RSUs. The RSUs to employees vest in one-fourth increments annually over a four-year period. The RSUs to existing non-employee directors vest one year from the date of grant or at the next Annual Shareholders Meeting, whichever comes first. New non-employee directors receive pro-rated RSU grants that vest on the same term as the annual RSU grants. The number of shares issued on the date the RSUs vest is net of the minimum statutory tax withholdings, which are paid in cash to the appropriate taxing authorities on behalf of the Company’s employees.

Stock Option Information

Option activity during fiscal 2019 under all the stock plans was as follows (in millions, except per share amounts):


	Stock Options Outstanding
	Number Outstanding	Weighted Average Exercise Price Per Share
Balance at December 31, 2018	6.2	$	200.79

Options granted	0.6	$	523.30
Options exercised	(1.3)	$	159.46
Options forfeited/expired	(0.1)	$	381.82
Balance at December 31, 2019	5.4	$	246.64

The aggregate intrinsic value of stock options exercised under the Company’s stock plans determined as of the date of option exercise was $512.0 million, $526.6 million, and $379.9 million during the years ended December 31, 2019, 2018, and 2017, respectively. Cash received from option exercises and employee stock purchase plans for the years ended December 31, 2019, 2018, and 2017, was $272.8 million, $236.6 million, and $415.5 million, respectively. The income tax benefit from stock options exercised was $109.7 million for the year ended December 31, 2019.

The following table summarizes significant ranges of outstanding and exercisable options as of December 31, 2019 (number of shares and aggregate intrinsic value in millions):


	Options Outstanding										Options Exercisable
Range of Exercise Prices	Number of Shares	Weighted Average Remaining Contractual Life	Weighted Average Exercise Price Per Share		Aggregate Intrinsic Value (1)		Number of Shares	Weighted Average Remaining Contractual Life	Weighted Average Exercise Price Per Share		Aggregate Intrinsic Value (1)
$86.88-$148.03	1.1	2.8	$	127.46			1.1		$	127.46
$150.50-$172.44	1.4	3.6	$	166.28			1.4		$	166.29
$172.76-$231.00	1.2	5.1	$	194.42			1.2		$	193.89
$231.11-$505.36	1.1	8.1	$	376.53			0.5		$	334.67
$508.19-$585.57	0.6	9.0	$	536.41			0.1		$	531.66
Total	5.4	5.3	$	246.64	$	1,844.4	4.3	4.4	$	195.76	$	1,702.4

As of December 31, 2019, a total of 5.2 million shares of stock options vested and expected to vest had a weighted-average remaining contractual life of 5.2 years, an aggregate intrinsic value of $1,833.1 million, and a weighted-average exercise price of $241.65.

Restricted Stock Units Information

RSU activity for the year ended December 31, 2019, was as follows (in millions, except per share amounts):


	Shares	Weighted Average Grant Date Fair Value
Unvested balance at December 31, 2018	2.0	$	295.70
Granted	0.8	541.36
Vested	(0.8)	258.87
Forfeited	(0.1)	382.52
Unvested balance at December 31, 2019	1.9	410.09

As of December 31, 2019, 1.7 million shares of RSUs were expected to vest with an aggregate intrinsic value of $1,032 million. The aggregate vesting date fair value of RSUs vested was $433.2 million, $334.3 million, and $144.2 million during the years ended December 31, 2019, 2018, and 2017, respectively.

Share-Based Compensation Expense

The following table summarizes share-based compensation expense (in millions):


	Years Ended December 31,
	2019		2018		2017
Cost of sales—products	$	46.6	$	36.4	$	28.1
Cost of sales—services	20.4		16.8		14.0
Total cost of sales	67.0		53.2		42.1
Selling, general and administrative	169.5		133.2		111.8
Research and development	101.4		76.2		56.0
Share-based compensation expense before income taxes	337.9		262.6		209.9
Income tax effect	70.2		54.3		49.2
Share-based compensation expense after income taxes	$	267.7	$	208.3	$	160.7

The Black-Scholes option pricing model is used to estimate the fair value of stock options granted under the Company’s share-based compensation plans and rights to acquire stock granted under the Company’s employee stock purchase plan. The weighted-average estimated fair values of stock options, the rights to acquire stock under the ESPP, and RSUs, as well as the weighted average assumptions used in calculating the fair values of stock options and rights to acquire stock under the ESPP that were granted during the years ended December 31, 2019, 2018, and 2017, were as follows:


	Years Ended December 31,
STOCK OPTION PLANS	2019			2018			2017
Risk-free interest rate	2.0		%	2.7		%	1.8		%
Expected term (years)	4.1			4.3			4.1
Volatility	30		%	33		%	25		%
Fair value at grant date	$	142.53		$	146.30		$	67.03

EMPLOYEE STOCK PURCHASE PLAN
Risk-free interest rate	2.1		%	2.1		%	1.2		%
Expected term (years)	1.2			1.3			1.2
Volatility	29		%	32		%	28		%
Fair value at grant date	$	148.99		$	135.84		$	79.77
RESTRICTED STOCK UNITS
Fair value at grant date	$	541.36		$	431.11		$	249.34

As share-based compensation expense recognized in the Consolidated Statements of Income during the years ended December 31, 2019, 2018, and 2017, is based on awards ultimately expected to vest, it has been reduced for estimated forfeitures.

As of December 31, 2019, there was a total of $110.1 million, $493.6 million, and $31.4 million of total unrecognized compensation expense related to unvested stock options, restricted stock units, and employee stock purchases, respectively. The unrecognized compensation expense is expected to be recognized over a weighted-average period of 2.5 years for unvested stock options, 2.2 years for unvested restricted stock units, and 1.4 years for rights granted to acquire common stock under the ESPP.

Consolidated Financial Statement Details (Tables)

12 Months Ended

Dec. 31, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Details of the Inventory Balance Sheet Item


	December 31,
	2019		2018
Inventory:
Raw materials	$	211.0	$	164.1
Work-in-process	75.9		40.0
Finished goods	308.6		204.9
Total inventory	$	595.5	$	409.0

Details of the Property, Plant and Equipment, Net Balance Sheet Item


			Useful Lives
Building			Up to 30 years
Building improvements			Up to 15 years
Leasehold improvements			Lesser of useful life or term of lease
Equipment and furniture			5 years
Operating lease assets			Greater of lease term or 1 to 5 years
Computer and office equipment			3 years
Enterprise-wide software			5 years
Purchased software			Lesser of 3 years or life of license


	December 31,
	2019		2018
Property, plant, and equipment, net:
Land	$	248.0	$	184.6
Building and building/leasehold improvements	408.3		266.2
Machinery and equipment	357.2		280.1
Operating lease assets—Intuitive System Leasing	293.8		150.2
Computer and office equipment	74.0		52.6
Capitalized software	182.2		157.8
Construction-in-process	272.5		156.7
Gross property, plant, and equipment	1,836.0		1,248.2
Less: Accumulated depreciation*	(563.1)		(436.2)
Total property, plant, and equipment, net	$	1,272.9	$	812.0

*Accumulated depreciation associated with operating lease assets—Intuitive System Leasing	(62.2)		(32.1)

Details of the Other Accrued Liabilities—Short Term Balance Sheet Item


	December 31,
	2019		2018
Other accrued liabilities—short-term
Taxes payable	$	37.9	$	39.1
Litigation-related accruals	5.8		55.0
Current portion of deferred purchase consideration payments	35.7		4.6
Current portion of contingent consideration	44.5		—
Other accrued liabilities	193.4		133.1
Total other accrued liabilities—short-term	$	317.3	$	231.8

Details of the Other Long-Term Liabilities Balance Sheet Item


	December 31,
	2019		2018
Other long-term liabilities:
Income taxes—long-term	$	258.6	$	270.2
Deferred revenue—long-term	27.4		33.0
Other long-term liabilities	132.3		35.4
Total other long-term liabilities	$	418.3	$	338.6

Supplemental Cash Flow Information

The following table provides supplemental cash flow information (in millions):


	Years Ended December 31,
	2019		2018		2017
Income taxes paid	$	158.6	$	179.2	$	147.5
Supplemental non-cash investing and financing activities:
Equipment transfers from inventory to property, plant, and equipment	$	210.6	$	125.7	$	65.8
Deferred payments and contingent consideration related to business combinations	$	86.6	$	16.7	$	—

Stockholders' Equity

12 Months Ended

Dec. 31, 2019

Equity [Abstract]

Stockholders' Equity

STOCKHOLDERS’ EQUITY

STOCK REPURCHASE PROGRAM

Through December 31, 2019, the Company’s Board of Directors (the “Board”) has authorized an aggregate of $7.5 billion of funding for the Company’s common stock repurchase program (the “Repurchase Program”) since its establishment in March 2009. The most recent authorization occurred in January 2019 when the Board increased the authorized amount available under the Repurchase Program to $2.0 billion. As of December 31, 2019, the remaining amount of share repurchases authorized by the Board under the Repurchase Program was approximately $1.7 billion.

The following table provides the stock repurchase activities during the years ended December 31, 2019, 2018, and 2017 (in millions, except per share amounts):


	Years Ended December 31,
	2019		2018		2017
Shares repurchased	0.6		—		7.3
Average price per share	$	481.35	$	—	$	310.32
Value of shares repurchased	$	269.5	$	—	$	2,274.0

The Company uses the par value method of accounting for its stock repurchases. As a result of share repurchase activities during the years ended December 31, 2019, 2018, and 2017, the Company reduced common stock and additional paid-in capital by an aggregate of $14.5 million, zero, and $152 million, respectively, and charged $255 million, zero, $2,122 million, respectively, to retained earnings.

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)

The components of accumulated other comprehensive income (loss), net of tax, for the years ended December 31, 2019, and 2018, are as follows (in millions):


	Year Ended December 31, 2019
	Gains (Losses) on Hedge Instruments		Unrealized Gains (Losses) on Available-for-Sale Securities		Foreign Currency Translation Gains (Losses)		Employee Benefit Plans		Total
Beginning balance	$	0.2	$	(9.8)	$	(0.3)	$	(3.4)	$	(13.3)
Other comprehensive income (loss) before reclassifications	5.8		30.7		0.3		(5.9)		30.9
Reclassified from accumulated other comprehensive (loss)	(5.3)		(0.5)		—		0.6		(5.2)
Net current-period other comprehensive income (loss)	0.5		30.2		0.3		(5.3)		25.7
Ending balance	$	0.7	$	20.4	$	—	$	(8.7)	$	12.4

	Year Ended December 31, 2018
	Gains (Losses) on Hedge Instruments		Unrealized Gains (Losses) on Available-for-Sale Securities		Foreign Currency Translation Gains (Losses)		Employee Benefit Plans		Total
Beginning balance	$	(2.4)	$	(11.3)	$	2.3	$	(4.1)	$	(15.5)
Other comprehensive income (loss) before reclassifications	3.6		0.3		(2.6)		0.4		1.7
Reclassified from accumulated other comprehensive income (loss)	(1.0)		1.2		—		0.3		0.5
Net current-period other comprehensive income (loss)	2.6		1.5		(2.6)		0.7		2.2
Ending balance	$	0.2	$	(9.8)	$	(0.3)	$	(3.4)	$	(13.3)

Valuation And Qualifying Accounts

12 Months Ended

Dec. 31, 2019

SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]

Valuation And Qualifying Accounts


	Balance at Beginning of Year		Additions		Deductions ⁽¹⁾		Balance at End of Year
Allowance for doubtful accounts, loan credit losses, and sales returns
Year ended December 31, 2019	$	20.4	$	46.9	$	(45.9)	$	21.4
Year ended December 31, 2018	$	14.6	$	46.0	$	(40.2)	$	20.4
Year ended December 31, 2017	$	10.8	$	36.1	$	(32.3)	$	14.6

(1)Primarily represents products returned.

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Allowance	$ 8.3	$ 8.2
Preferred stock, shares authorized	2,500,000	2,500,000
Preferred stock, par value (usd per share)	$ 0.001	$ 0.001
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, shares authorized	300,000,000.0	300,000,000.0
Common stock, par value (usd per share)	$ 0.001	$ 0.001
Common stock, shares issued	116,000,000.0	114,500,000
Common stock, shares outstanding	116,000,000.0	114,500,000

Leases - Supplemental Cash Flow Information (Details) $ in Millions	12 Months Ended
	Dec. 31, 2019 USD ($)
Leases [Abstract]
Cash paid for leases that were included within operating cash outflows	$ 18.8
Right-of-use assets recognized related to new lease obligations	$ 21.5

Share-Based Compensation - Summary of RSU Activity (Details) - Restricted Stock Units (RSUs) - $ / shares shares in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Shares
Unvested beginning balance (shares)	2.0
Granted (shares)	0.8
Vested (shares)	(0.8)
Canceled (shares)	(0.1)
Unvested ending balance (shares)	1.9	2.0
Weighted Average Grant Date Fair Value
Unvested beginning balance (usd per share)	$ 295.70
Fair value at grant date (usd per share)	541.36	$ 431.11	$ 249.34
Vested (usd per share)	258.87
Canceled (usd per share)	382.52
Unvested ending balance (usd per share)	$ 410.09	$ 295.70

Stockholders' Equity - Schedule Of Stock Repurchase Activities (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Equity [Abstract]
Shares repurchased (shares)	0.6	0.0	7.3
Average price per share (usd per share)	$ 481.35	$ 0	$ 310.32
Value of shares repurchased	$ 269.5	$ 0.0	$ 2,274.0

Net Income Per Share

12 Months Ended

Dec. 31, 2019

Earnings Per Share [Abstract]

Net Income Per Share

NET INCOME PER SHARE

The following table presents the computation of basic and diluted net income per share attributable to Intuitive Surgical, Inc. (in millions, except per share amounts):


	Years Ended December 31,
	2019		2018		2017
Numerator:
Net income attributable to Intuitive Surgical, Inc.	$	1,379.3	$	1,127.9	$	670.9
Denominator:
Weighted average shares outstanding used in basic calculation	115.4		113.7		111.7
Add: dilutive effect of potential common shares	4.1		5.1		4.6
Weighted average shares outstanding used in diluted calculation	119.5		118.8		116.3
Net income per share attributable to Intuitive Surgical, Inc.:
Basic	$	11.95	$	9.92	$	6.01
Diluted	$	11.54	$	9.49	$	5.77

Share-based compensation awards of approximately 0.7 million, 0.4 million, and 0.2 million shares for the years ended December 31, 2019, 2018, and 2017, respectively, were outstanding but were not included in the computation of diluted net income per share attributable to Intuitive Surgical, Inc. common stockholders, because the effect of including such shares would have been anti-dilutive in the periods presented.

Leases - Schedule of Maturities of Operating Lease Liabilities (Details) $ in Millions	Dec. 31, 2019 USD ($)
Leases [Abstract]
2020	$ 9.6
2021	19.7
2022	14.7
2023	12.8
2024	8.4
2025 and thereafter	22.4
Total lease payments	87.6
Less imputed interest	(11.2)
Total operating lease liabilities	$ 76.4

Leases (Tables)

12 Months Ended

Dec. 31, 2019

Leases [Abstract]

Sales-type Lease Receivable

Lease receivables relating to sales-type lease arrangements are presented on the Consolidated Balance Sheets as follows (in millions):


	December 31,
	2019		2018
Gross lease receivables	$	191.9	$	150.4
Unearned income	(10.1)		(6.3)
Allowance for credit loss	(1.2)		(1.0)
Net investment in sales-type leases	$	180.6	$	143.1
Reported as:
Prepaids and other current assets	$	63.1	$	51.2
Intangible and other assets, net	117.5		91.9
Total, net	$	180.6	$	143.1

Sales-type Lease Receivable

The following table presents revenue from Intuitive System Leasing arrangements (in millions):


	Years Ended December 31,
	2019		2018		2017
Sales-type lease revenue	$	81.6	$	69.8	$	49.5
Operating lease revenue	$	106.9	$	51.4	$	25.9

Schedule of Contractual Maturities of Gross Lease Receivables

Contractual maturities of gross lease receivables as of December 31, 2019, are as follows (in millions):


Fiscal Year	Amount

2020	$	63.5
2021	52.9
2022	36.2
2023	22.1
2024	15.4
2025 and thereafter	1.8
Total	$	191.9

Schedule of Operating Lease Payments

The Company’s operating lease terms are generally less than seven years. Future minimum lease payments related to the non-cancellable portion of operating leases (which excludes contingent payments related to usage-based arrangements) as of December 31, 2019, are as follows (in millions):


Fiscal Year	Amount

2020	$	146.5
2021	134.2
2022	116.0
2023	86.6
2024	40.6
2025 and thereafter	10.8
Total	$	534.7

Supplemental Cash Flow and Balance Sheet Information

Supplemental cash flow information for the year ended December 31, 2019, related to operating leases was as follows (in millions):


	Amount
Cash paid for leases that were included within operating cash outflows	$	18.8
Right-of-use assets recognized related to new lease obligations	$	21.5

Supplemental Balance Sheet Information

Supplemental balance sheet information, as of December 31, 2019, related to operating leases was as follows (in millions, except lease term and discount rate):


Reported as:	Amount
Intangible and other assets, net (Right-of-use assets)	$	74.4
Other accrued liabilities	$	7.7
Other long-term liabilities	68.7
Total lease liabilities	$	76.4
Weighted average remaining lease term	6.1 years
Weighted average discount rate	3.4		%

Schedule of Maturities of Operating Lease Liabilities

As of December 31, 2019, the future payments related to the Company's operating lease liabilities are scheduled as follows (in millions):


Fiscal Year	Amount
2020	$	9.6
2021	19.7
2022	14.7
2023	12.8
2024	8.4
2025 and thereafter	22.4
Total lease payments	$	87.6
Less imputed interest	(11.2)
Total operating lease liabilities	$	76.4

Contractual Maturities of Gross Lease Receivables

Contractual maturities of gross lease receivables as of December 31, 2018, are as follows (in millions):


Fiscal Year	Amount
2019	$	50.8
2020	46.5
2021	29.7
2022	14.9
2023	7.5
2024 and thereafter	1.0
Total lease payments	$	150.4

Schedule Of Future Minimum Lease Commitments Under Operating Leases


Fiscal Year	Amount
2019	$	88.0
2020	85.8
2021	68.8
2022	51.3
2023	25.4
2024 and thereafter	1.9
Total lease payments	$	321.2

Lessee Information

Operating Leases. Future minimum lease commitments under the Company's operating leases as of December 31, 2018, are as follows (in millions):


Fiscal Year	Amount
2019	$	15.1
2020	14.5
2021	12.7
2022	11.2
2023	11.0
2024 and thereafter	30.9
Total lease payments	$	95.4

Summary Of Significant Accounting Policies

12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Summary Of Significant Accounting Policies

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

Use of Estimates

Concentrations of Credit Risk and Other Risks and Uncertainties

The Company’s accounts receivable are derived from net revenue to customers and distributors located throughout the world. The Company performs credit evaluations of its customers’ financial condition and, generally, requires no collateral from its customers. The Company provides reserves for potential credit losses but has not experienced significant losses to date. As of December 31, 2019, and 2018, 66% and 71%, respectively, of accounts receivable were from domestic customers. No single customer represented more than 10% of total revenue for the years ended December 31, 2019, 2018, and 2017.

During the years ended December 31, 2019, 2018, and 2017, domestic revenue accounted for 70%, 71%, and 73% of total revenue, respectively, while outside of the U.S. revenue accounted for 30%, 29%, and 27%, respectively, of total revenue for each of the years then ended.

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity from date of purchase of 90 days or less to be cash equivalents.

Restricted Cash

Investments

Fair Value Measurements

Inventory

Property, Plant, and Equipment


			Useful Lives
Building			Up to 30 years
Building improvements			Up to 15 years
Leasehold improvements			Lesser of useful life or term of lease
Equipment and furniture			5 years
Operating lease assets			Greater of lease term or 1 to 5 years
Computer and office equipment			3 years
Enterprise-wide software			5 years
Purchased software			Lesser of 3 years or life of license

Depreciation expense for the years ended December 31, 2019, 2018, and 2017, was $156.7 million, $105.9 million, and $82.1 million, respectively.

Capitalized Software Costs for Internal Use

Business Combinations

Goodwill and Intangible Assets

Impairment of Long-lived Assets

Revenue Recognition

Assets Recognized from the Costs to Obtain a Contract with a Customer

Intuitive System Leasing

Other Leasing Arrangements

Allowances for Sales Returns and Doubtful Accounts

Share-Based Compensation

Risk-Free Interest Rate: The risk-free interest rate is based on the U.S. treasury yield curve in effect at the time of grant for the expected term of the stock option.

Computation of Net Income per Share

Research and Development Expenses

Foreign Currency and Other Hedging Instruments

Derivatives that are not designated as hedging instruments and the ineffective portions of cash flow hedges are adjusted to fair value through earnings in interest and other income, net.

Income Taxes

Segments

Legal Contingencies

Recently Adopted Accounting Pronouncements

Leases

The primary impact for the Company was the balance sheet recognition of ROU assets and lease liabilities for operating leases as a lessee.

Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract

Recent Accounting Pronouncements Not Yet Adopted

Financial Instruments (Topic 326)

Consolidated Financial Statement Details

12 Months Ended

Dec. 31, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Consolidated Financial Statement Details

CONSOLIDATED FINANCIAL STATEMENT DETAILS

The following tables provide details of selected consolidated financial statement items (in millions):


	December 31,
	2019		2018
Inventory:
Raw materials	$	211.0	$	164.1
Work-in-process	75.9		40.0
Finished goods	308.6		204.9
Total inventory	$	595.5	$	409.0


	December 31,
	2019		2018
Property, plant, and equipment, net:
Land	$	248.0	$	184.6
Building and building/leasehold improvements	408.3		266.2
Machinery and equipment	357.2		280.1
Operating lease assets—Intuitive System Leasing	293.8		150.2
Computer and office equipment	74.0		52.6
Capitalized software	182.2		157.8
Construction-in-process	272.5		156.7
Gross property, plant, and equipment	1,836.0		1,248.2
Less: Accumulated depreciation*	(563.1)		(436.2)
Total property, plant, and equipment, net	$	1,272.9	$	812.0

*Accumulated depreciation associated with operating lease assets—Intuitive System Leasing	(62.2)		(32.1)


	December 31,
	2019		2018
Other accrued liabilities—short-term
Taxes payable	$	37.9	$	39.1
Litigation-related accruals	5.8		55.0
Current portion of deferred purchase consideration payments	35.7		4.6
Current portion of contingent consideration	44.5		—
Other accrued liabilities	193.4		133.1
Total other accrued liabilities—short-term	$	317.3	$	231.8


	December 31,
	2019		2018
Other long-term liabilities:
Income taxes—long-term	$	258.6	$	270.2
Deferred revenue—long-term	27.4		33.0
Other long-term liabilities	132.3		35.4
Total other long-term liabilities	$	418.3	$	338.6

Supplemental Cash flow Information

The following table provides supplemental cash flow information (in millions):


	Years Ended December 31,
	2019		2018		2017
Income taxes paid	$	158.6	$	179.2	$	147.5
Supplemental non-cash investing and financing activities:
Equipment transfers from inventory to property, plant, and equipment	$	210.6	$	125.7	$	65.8
Deferred payments and contingent consideration related to business combinations	$	86.6	$	16.7	$	—

Leases - Supplemental Balance Sheet Information (Details) $ in Millions	Dec. 31, 2019 USD ($)
Leases [Abstract]
Intangible and other assets, net (Right-of-use assets)	$ 74.4
Other accrued liabilities	7.7
Other long-term liabilities	68.7
Total lease liabilities	$ 76.4
Weighted average remaining lease term	6 years 1 month 6 days
Weighted average discount rate	3.40%

Consolidated Financial Statement Details - Other Accrued Liabilities—Short Term (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Taxes payable	$ 37.9	$ 39.1
Litigation-related accruals	5.8	55.0
Current portion of deferred purchase consideration payments	35.7	4.6
Current portion of contingent consideration	44.5	0.0
Other accrued liabilities	193.4	133.1
Other Liabilities, Current	$ 317.3	$ 231.8

Goodwill and Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Summary of Changes in Goodwill

The following table summarizes the changes in the carrying amount of goodwill (in millions):


	Amount
Balance at December 31, 2017	$	201.1
Acquisition activity	40.2
Translation and other	(0.7)
Balance at December 31, 2018	240.6
Acquisition activity	65.4
Translation and other	1.2
Balance at December 31, 2019	$	307.2

Schedule of Intangible Assets

The following table summarizes the components of gross intangible asset, accumulated amortization, and net intangible asset balances as of December 31, 2019, and 2018 (in millions):


	December 31, 2019										December 31, 2018
	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount
Patents and developed technology	$	186.7	$	(149.0)	$	37.7	$	158.7	$	(144.7)	$	14.0
Distribution rights and others	91.3		(44.9)		46.4		40.2		(12.9)		27.3
Customer relationships	57.7		(29.7)		28.0		48.5		(23.1)		25.4
Total intangible assets	$	335.7	$	(223.6)	$	112.1	$	247.4	$	(180.7)	$	66.7

Schedule Of Estimated Future Amortization Expense Of Intangible Assets

The estimated future amortization expense related to intangible assets as of December 31, 2019, is as follows (in millions):


Fiscal Year	Amount
2020	$	46.1
2021	18.7
2022	16.0
2023	11.5
2024	9.4
2025 and thereafter	10.4
Total	$	112.1

Leases - Additional Information (Details) $ in Millions	12 Months Ended
Leases - Additional Information (Details) $ in Millions	Dec. 31, 2019 USD ($)
Leases [Abstract]
Operating lease expense	$ 19.1

Revenue (Tables)

12 Months Ended

Dec. 31, 2019

Revenue from Contract with Customer [Abstract]

Revenue Disaggregated by Types and Geography

The following table presents revenue disaggregated by types and geography (in millions):


	Years Ended December 31,
U.S.	2019		2018		2017
Instruments and accessories	$	1,790.4	$	1,485.2	$	1,263.1
Systems	830.7		692.2		603.5
Services	508.4		456.1		419.2
Total U.S. revenue	$	3,129.5	$	2,633.5	$	2,285.8

Outside of U.S. (“OUS”)
Instruments and accessories	$	617.8	$	476.8	$	373.8
Systems	515.4		434.9		324.9
Services	215.8		179.0		153.7
Total OUS revenue	$	1,349.0	$	1,090.7	$	852.4

Total
Instruments and accessories	$	2,408.2	$	1,962.0	$	1,636.9
Systems	1,346.1		1,127.1		928.4
Services	724.2		635.1		572.9
Total revenue	$	4,478.5	$	3,724.2	$	3,138.2

Summary of Contract Assets and Liabilities

The following information summarizes the Company’s contract assets and liabilities (in millions):



	As of
	December 31, 2019		December 31, 2018
Contract assets	$	20.8	$	12.4
Deferred revenue	$	365.2	$	327.3

Sales-type Lease Receivable

The following table presents revenue from Intuitive System Leasing arrangements (in millions):


	Years Ended December 31,
	2019		2018		2017
Sales-type lease revenue	$	81.6	$	69.8	$	49.5
Operating lease revenue	$	106.9	$	51.4	$	25.9

Operating Lease Revenue

The following table presents revenue from Intuitive System Leasing arrangements (in millions):


	Years Ended December 31,
	2019		2018		2017
Sales-type lease revenue	$	81.6	$	69.8	$	49.5
Operating lease revenue	$	106.9	$	51.4	$	25.9

Consolidated Statements Of Comprehensive Income - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Statement of Comprehensive Income [Abstract]
Net income attributable to Intuitive Surgical, Inc.	$ 1,379.3	$ 1,127.9	$ 670.9
Other comprehensive income (loss):
Change in foreign currency translation gains (losses)	0.3	(2.6)	3.6
Available-for-sale investments (net of tax):
Change in unrealized gains (losses)	30.7	0.3	(2.7)
Less: Reclassification adjustment for (gains) losses on investments	(0.5)	1.2	0.0
Net change	30.2	1.5	(2.7)
Derivative instruments (net of tax):
Change in unrealized gains (losses)	5.8	3.6	(8.6)
Less: Reclassification adjustment for (gains) losses on derivative instruments	(5.3)	(1.0)	1.2
Net change	0.5	2.6	(7.4)
Employee benefit plans (net of tax):
Change in unrealized gains (losses)	(5.9)	0.4	(0.3)
Less: Reclassification adjustment for losses on employee benefit plans	0.6	0.3	0.2
Net change	(5.3)	0.7	(0.1)
Other comprehensive gains (losses)	25.7	2.2	(6.6)
Total comprehensive income attributable to Intuitive Surgical, Inc.	$ 1,405.0	$ 1,130.1	$ 664.3

Financial Instruments - Schedule Of Available-For-Sale Investments With Unrealized Losses (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Schedule of Available-for-sale Securities [Line Items]
Unrealized losses less than 12 months Fair Value	$ 519.4	$ 1,434.1
Unrealized losses less than 12 months	(0.5)	(2.8)
Unrealized losses 12 months or greater Fair Value	133.0	1,427.6
Unrealized losses 12 months or greater	(0.3)	(11.1)
Total Fair Value	652.4	2,861.7
Total Unrealized Losses	(0.8)	(13.9)
Corporate securities
Schedule of Available-for-sale Securities [Line Items]
Unrealized losses less than 12 months Fair Value	237.0	727.4
Unrealized losses less than 12 months	(0.2)	(1.7)
Unrealized losses 12 months or greater Fair Value	0.0	409.6
Unrealized losses 12 months or greater	0.0	(3.1)
Total Fair Value	237.0	1,137.0
Total Unrealized Losses	(0.2)	(4.8)
U.S. treasuries
Schedule of Available-for-sale Securities [Line Items]
Unrealized losses less than 12 months Fair Value	236.5	478.7
Unrealized losses less than 12 months	(0.2)	(0.9)
Unrealized losses 12 months or greater Fair Value	87.5	592.8
Unrealized losses 12 months or greater	(0.2)	(4.4)
Total Fair Value	324.0	1,071.5
Total Unrealized Losses	(0.4)	(5.3)
U.S. government agencies
Schedule of Available-for-sale Securities [Line Items]
Unrealized losses less than 12 months Fair Value	45.9	228.0
Unrealized losses less than 12 months	(0.1)	(0.2)
Unrealized losses 12 months or greater Fair Value	45.5	425.2
Unrealized losses 12 months or greater	(0.1)	(3.6)
Total Fair Value	91.4	653.2
Total Unrealized Losses	$ (0.2)	$ (3.8)

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2019

Income Tax Disclosure [Abstract]

Schedule Of Income Before Provision For Income Taxes

Income before provision for income taxes for the years ended December 31, 2019, 2018, and 2017, consisted of the following (in millions):


	Years Ended December 31,
	2019		2018		2017
U.S.	$	1,053.7	$	852.7	$	774.7
Foreign	448.5		426.8		330.1
Total income before provision for income taxes	$	1,502.2	$	1,279.5	$	1,104.8

Schedule Of Provision For Income Taxes

The provision for income taxes for the years ended December 31, 2019, 2018, and 2017, consisted of the following (in millions):


	Years Ended December 31,
	2019		2018		2017
Current
Federal	$	82.0	$	89.5	$	352.1
State	26.5		21.1		13.0
Foreign	18.0		9.9		8.7
	$	126.5	$	120.5	$	373.8
Deferred
Federal	$	8.5	$	(4.1)	$	62.8
State	3.2		(0.3)		(0.3)
Foreign	(17.8)		38.4		(2.4)
	$	(6.1)	$	34.0	$	60.1
Total income tax expense	$	120.4	$	154.5	$	433.9

Schedule Of Income Tax Difference From The Statutory Rate


	Years Ended December 31,
	2019		2018		2017
Federal tax at statutory rate	$	315.5	$	268.7	$	386.7
Increase (reduction) in tax resulting from:
State taxes, net of federal benefits	29.7		20.8		16.0
Foreign rate differential	(56.2)		(44.7)		(115.7)
U.S. tax on foreign earnings	55.0		43.7		8.4
Research and development credit	(32.7)		(25.2)		(15.3)
Share-based compensation not benefited	13.5		9.9		10.8
Domestic production activities deduction	—		—		(7.9)
Reversal of unrecognized tax benefits	(8.4)		(5.2)		(62.4)

Tax Cuts and Jobs Act impact	—		0.5		317.8
Excess tax benefits related to share-based compensation arrangements	(146.5)		(116.2)		(102.8)
Deferred tax remeasurement due to Swiss Tax Reform	(51.3)		—		—
Other	1.8		2.2		(1.7)
Total income tax expense	$	120.4	$	154.5	$	433.9

Schedule Of Deferred Tax Assets


	December 31,
	2019		2018
Deferred tax assets:
Share-based compensation expense	$	95.6	$	87.2
Expenses deducted in later years for tax purposes	42.0		29.1
Intangible assets	362.3		351.9
Research and other credits	56.1		40.1
Other	10.4		9.0
Gross deferred tax assets	$	566.4	$	517.3
Valuation allowance	(57.2)		(42.3)
Deferred tax assets	$	509.2	$	475.0
Deferred tax liabilities:
Fixed assets	$	(75.3)	$	(42.2)
Intangible assets	(8.3)		(7.5)
Other	—		(0.1)
Deferred tax liabilities	$	(83.6)	$	(49.8)
Net deferred tax assets	$	425.6	$	425.2

Net Income Per Share - Additional Information (Details) - shares shares in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Earnings Per Share [Abstract]
Employee stock options excluded from computation of diluted net income per share	0.7	0.4	0.2

Financial Instruments - Gross Notional Amounts for Outstanding Derivatives (Details) - Forward contracts - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Derivatives Designated as Hedging Instruments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Notional amounts of outstanding currency forward contracts	$ 154.5	$ 183.0
Derivatives Designated as Hedging Instruments \| Prepaid and other current assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Notional amounts of outstanding currency forward contracts	1.3	3.1
Derivatives Designated as Hedging Instruments \| Other accrued liabilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Notional amounts of outstanding currency forward contracts	0.5	0.9
Derivatives Not Designated as Hedging Instruments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Notional amounts of outstanding currency forward contracts	227.2	182.7
Derivatives Not Designated as Hedging Instruments \| Prepaid and other current assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Notional amounts of outstanding currency forward contracts	2.2	4.1
Derivatives Not Designated as Hedging Instruments \| Other accrued liabilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Notional amounts of outstanding currency forward contracts	$ 0.7	$ 1.1

Income Taxes - Schedule Of Provision For Income Taxes (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Current income taxes, Federal	$ 82.0	$ 89.5	$ 352.1
Current income taxes, State	26.5	21.1	13.0
Current income taxes, Foreign	18.0	9.9	8.7
Current income taxes	126.5	120.5	373.8
Deferred income taxes, Federal	8.5	(4.1)	62.8
Deferred income taxes, State	3.2	(0.3)	(0.3)
Deferred income taxes, Foreign	(17.8)	38.4	(2.4)
Deferred income taxes	(6.1)	34.0	60.1
Total income tax expense	$ 120.4	$ 154.5	$ 433.9

Goodwill and Intangible Assets - Additional Information (Details) - USD ($) $ in Millions						3 Months Ended	12 Months Ended
	Aug. 31, 2019	Jan. 05, 2019	Dec. 11, 2018	Aug. 17, 2018	May 25, 2018	Dec. 31, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Business Acquisition [Line Items]
Deferred payments and contingent consideration related to business combinations							$ 86.6	$ 16.7	$ 0.0
Payment of deferred purchase consideration							22.6	0.3	0.0
Goodwill						$ 307.2	307.2	240.6	201.1
Amortization of intangible assets							43.0	14.2	12.9
Amortization expense related to intangible assets							43.0	$ 14.2	$ 12.9
Chindex
Business Acquisition [Line Items]
Total purchase consideration		$ 66.0
Deferred payments and contingent consideration related to business combinations		64.7
Cash payments		1.3
Estimated total undiscounted contingent consideration		81.0
Decrease in undiscounted expected contingent consideration							(6.0)
Payment of deferred purchase consideration							16.5
Additional payment of deferred purchase consideration							7.2
Net tangible assets acquired		1.7
Intangible assets acquired		58.6
Goodwill		$ 5.7
Weighted average useful life		2 years 10 months 24 days
Chindex \| Distribution rights and others
Business Acquisition [Line Items]
Intangible assets acquired		$ 48.2
Chindex \| Customer relationships
Business Acquisition [Line Items]
Intangible assets acquired		$ 10.4
Schölly
Business Acquisition [Line Items]
Total purchase consideration	$ 101.4
Cash payments	34.4
Net tangible assets acquired	10.7
Intangible assets acquired	31.0
Goodwill	$ 59.7
Weighted average useful life	6 years 7 months 6 days
Deferred Purchase Consideration Payments	$ 67.0					37.3	$ 37.3
Inventory acquired	6.7
Cash acquired	$ 1.4
Intangible assets adjustment						0.5
Goodwill adjustment						0.4
Schölly \| Manufacturing process technology
Business Acquisition [Line Items]
Intangible assets						28.0
Schölly \| Non-compete provision
Business Acquisition [Line Items]
Intangible assets						$ 3.0
Vattikuti Technologies Pvt. Ltd.
Business Acquisition [Line Items]
Cash payments					$ 36.2
Net tangible assets acquired					4.1
Intangible assets acquired					24.2
Goodwill					$ 7.3
Weighted average useful life					4 years 3 months 18 days
Net impact of measurement-period adjustment					$ 2.5
InTouch
Business Acquisition [Line Items]
Total purchase consideration				$ 38.7
Deferred payments and contingent consideration related to business combinations				16.7
Cash payments				22.0
Intangible assets acquired				13.3
Goodwill				$ 25.4
Weighted average useful life				5 years 8 months 12 days
Unison Surgicals Company
Business Acquisition [Line Items]
Cash payments			$ 35.4
Net tangible assets acquired			13.1
Intangible assets acquired			17.3
Goodwill			$ 5.0
Weighted average useful life			6 years 7 months 6 days
Cash acquired			$ 7.6

Summary Of Significant Accounting Policies - Estimated Useful Lives Of Assets (Details)	12 Months Ended
	Dec. 31, 2019
Building
Property, Plant and Equipment [Line Items]
Useful Lives	30 years
Building improvements
Property, Plant and Equipment [Line Items]
Useful Lives	15 years
Equipment and furniture
Property, Plant and Equipment [Line Items]
Useful Lives	5 years
Operating lease assets \| Maximum
Property, Plant and Equipment [Line Items]
Useful Lives	5 years
Operating lease assets \| Minimum
Property, Plant and Equipment [Line Items]
Useful Lives	1 year
Computer and office equipment
Property, Plant and Equipment [Line Items]
Useful Lives	3 years
Enterprise-wide software
Property, Plant and Equipment [Line Items]
Useful Lives	5 years
Purchased software
Property, Plant and Equipment [Line Items]
Useful Lives	3 years

Revenue - Remaining Performance Obligations (Details) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01 $ in Millions	Dec. 31, 2019 USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligations	5 years
Transaction price allocated to remaining performance obligations	$ 1,597

Leases - Contractual Maturities of Gross Lease Receivables (Details) $ in Millions	Dec. 31, 2018 USD ($)
Leases [Abstract]
2019	$ 50.8
2020	46.5
2021	29.7
2022	14.9
2023	7.5
2024 and thereafter	1.0
Total lease payments	$ 150.4

Financial Instruments

12 Months Ended

Dec. 31, 2019

Fair Value Disclosures [Abstract]

Financial Instruments

FINANCIAL INSTRUMENTS

Cash, Cash Equivalents, and Investments


									Reported as:
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value		Cash and Cash Equivalents		Short-term Investments		Long-term Investments
December 31, 2019
Cash	$	413.1	$	—	$	—	$	413.1	$	413.1	$	—	$	—
Level 1:
Money market funds	726.8		—		—		726.8		726.8		—		—
U.S. treasuries	1,935.8		9.7		(0.4)		1,945.1		—		890.8		1,054.3
Subtotal	2,662.6		9.7		(0.4)		2,671.9		726.8		890.8		1,054.3
Level 2:
Commercial paper	165.1		—		—		165.1		25.5		139.6		—
Corporate securities	2,096.1		16.8		(0.2)		2,112.7		—		798.5		1,314.2
U.S. government agencies	418.3		1.1		(0.2)		419.2		—		209.6		209.6
Non-U.S. government securities	4.5		—		—		4.5		—		4.5		—
Municipal securities	58.4		0.3		—		58.7		2.2		11.1		45.4
Subtotal	2,742.4		18.2		(0.4)		2,760.2		27.7		1,163.3		1,569.2



Total assets measured at fair value	$	5,818.1	$	27.9	$	(0.8)	$	5,845.2	$	1,167.6	$	2,054.1	$	2,623.5


									Reported as:
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value		Cash and Cash Equivalents		Short-term Investments		Long-term Investments
December 31, 2018
Cash	$	269.4	$	—	$	—	$	269.4	$	269.4	$	—	$	—
Level 1:
Money market funds	569.1		—		—		569.1		569.1		—		—
U.S. treasuries	1,477.8		1.7		(5.3)		1,474.2		10.0		897.8		566.4
Subtotal	2,046.9		1.7		(5.3)		2,043.3		579.1		897.8		566.4
Level 2:
Commercial paper	110.7		—		—		110.7		1.4		109.3		—
Corporate securities	1,607.8		1.3		(4.8)		1,604.3		8.0		724.5		871.8
U.S. government agencies	791.8		0.3		(3.8)		788.3		—		468.9		319.4

Municipal securities	18.4		—		—		18.4		—		4.7		13.7
Subtotal	2,528.7		1.6		(8.6)		2,521.7		9.4		1,307.4		1,204.9



Total assets measured at fair value	$	4,845.0	$	3.3	$	(13.9)	$	4,834.4	$	857.9	$	2,205.2	$	1,771.3

As of December 31, 2018, the Company also recorded $36.5 million of restricted cash equivalents (comprised of money market funds and U.S. treasuries, which would be considered highly liquid investments with original maturity dates that are 90 days or less) in connection with a concluded legal matter in prepaids and other current assets in the accompanying Consolidated Balance Sheets.


	Amortized Cost		Fair Value
Mature in less than one year	$	2,082.4	$	2,087.7
Mature in one to five years	2,595.8		2,617.6

Total	$	4,678.2	$	4,705.3

Realized gains and losses, net of tax, were not material for any of the periods presented.

As of December 31, 2019, and 2018, net unrealized gains/(losses) on investments of $20.4 million and $(9.8) million, net of tax, respectively, were included in accumulated other comprehensive income/(loss) in the accompanying Consolidated Balance Sheets.

The following tables present the breakdown of the available-for-sale investments with unrealized losses at December 31, 2019, and 2018 (in millions):


	Unrealized losses less than 12 months						Unrealized losses 12 months or greater						Total
December 31, 2019	Fair Value		Unrealized Losses		Fair Value		Unrealized Losses		Fair Value		Unrealized Losses
Corporate securities	$	237.0	$	(0.2)	$	—	$	—	$	237.0	$	(0.2)
U.S. treasuries	236.5		(0.2)		87.5		(0.2)		324.0		(0.4)
U.S. government agencies	45.9		(0.1)		45.5		(0.1)		91.4		(0.2)
Total	$	519.4	$	(0.5)	$	133.0	$	(0.3)	$	652.4	$	(0.8)
December 31, 2018
Corporate securities	$	727.4	$	(1.7)	$	409.6	$	(3.1)	$	1,137.0	$	(4.8)
U.S. treasuries	478.7		(0.9)		592.8		(4.4)		1,071.5		(5.3)
U.S. government agencies	228.0		(0.2)		425.2		(3.6)		653.2		(3.8)
Total	$	1,434.1	$	(2.8)	$	1,427.6	$	(11.1)	$	2,861.7	$	(13.9)

The unrealized losses on the available-for-sale investments are related to corporate securities and government securities. The Company determined these unrealized losses to be temporary. Factors considered in determining whether a loss is temporary included the length of time and extent to which the investment’s fair value has been less than the cost basis, the

financial condition and near-term prospects of the investee, the extent of the loss related to credit of the issuer, the expected cash flows from the security, the Company’s intent to sell the security, and whether or not the Company will be required to sell the security before the recovery of its amortized cost.

Foreign currency derivatives

The objective of the Company’s hedging program is to mitigate the impact of changes in currency exchange rates on net cash flow from foreign currency-denominated sales, expenses, and intercompany balances and other monetary assets or liabilities denominated in currencies other than the U.S. dollar (“USD”). The derivative assets and liabilities are measured using Level 2 fair value inputs.

Cash Flow Hedges. The Company enters into currency forward contracts as cash flow hedges to hedge certain forecasted revenue transactions denominated in currencies other than the USD, primarily the Euro (“EUR”), the British Pound (“GBP”), the Japanese Yen (“JPY”), and the Korean Won (“KRW”). The Company also enters into currency forward contracts as cash flow hedges to hedge certain forecasted expense transactions denominated in EUR and Swiss Franc (“CHF”).

For these derivatives, the Company reports the unrealized after-tax gain or loss from the hedge as a component of accumulated other comprehensive income/(loss) in stockholders’ equity and reclassifies the amount into earnings in the same period in which the hedge transaction affects earnings. The amounts reclassified to revenue and expenses related to the hedged transactions and the ineffective portions of cash flow hedges were not material for the periods presented.

Other Derivatives Not Designated as Hedging Instruments. Other derivatives not designated as hedging instruments consist primarily of forward contracts that the Company uses to hedge intercompany balances and other monetary assets or liabilities denominated in currencies other than the USD, primarily the EUR, GBP, JPY, KRW, CHF, Indian Rupee, and New Taiwan Dollar.

These derivative instruments are used to hedge against balance sheet foreign currency exposures. The related gains and losses were as follows (in millions):


	Years Ended December 31,
	2019		2018		2017
Recognized gains (losses) in interest and other income, net	$	6.4	$	8.7	$	(9.2)
Foreign exchange gains (losses) related to balance sheet re-measurement	$	(1.5)	$	(2.6)	$	9.7

The notional amounts for derivative instruments provide one measure of the transaction volume. Total gross notional amounts (in USD) for derivatives and the aggregate gross fair value outstanding at the end of each period were as follows (in millions):


	Derivatives Designated as Hedging Instruments						Derivatives Not Designated as Hedging Instruments
	December 31, 2019		December 31, 2018		December 31, 2019		December 31, 2018
Notional amounts:
Forward contracts	$	154.5	$	183.0	$	227.2	$	182.7
Gross fair value recorded in:
Prepaid and other current assets	$	1.3	$	3.1	$	2.2	$	4.1
Other accrued liabilities	$	0.5	$	0.9	$	0.7	$	1.1

Financial Instruments - Summary Of Cash And Available-For-Sale Securities (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Schedule of Available-for-sale Securities [Line Items]
Cash and Cash Equivalents	$ 1,167.6	$ 857.9
Total	4,678.2
Total assets measured at fair value, Amortized Cost	5,818.1	4,845.0
Gross Unrealized Gains	27.9	3.3
Gross Unrealized Losses	0.8	13.9
Fair Value	4,705.3
Total assets measured at fair value, Fair Value	5,845.2	4,834.4
Short-term Investments	2,054.1	2,205.2
Long-term Investments	2,623.5	1,771.3
Cash
Schedule of Available-for-sale Securities [Line Items]
Cash and Cash Equivalents	413.1	269.4
Fair Value	413.1	269.4
Level 1
Schedule of Available-for-sale Securities [Line Items]
Cash and Cash Equivalents	726.8	579.1
Total	2,662.6	2,046.9
Gross Unrealized Gains	9.7	1.7
Gross Unrealized Losses	0.4	5.3
Fair Value	2,671.9	2,043.3
Short-term Investments	890.8	897.8
Long-term Investments	1,054.3	566.4
Level 1 \| Money market funds
Schedule of Available-for-sale Securities [Line Items]
Cash and Cash Equivalents	726.8	569.1
Fair Value	726.8	569.1
Short-term Investments	0.0	0.0
Long-term Investments	0.0	0.0
Level 1 \| U.S. treasuries
Schedule of Available-for-sale Securities [Line Items]
Cash and Cash Equivalents	0.0	10.0
Total	1,935.8	1,477.8
Gross Unrealized Gains	9.7	1.7
Gross Unrealized Losses	0.4	5.3
Fair Value	1,945.1	1,474.2
Short-term Investments	890.8	897.8
Long-term Investments	1,054.3	566.4
Level 2
Schedule of Available-for-sale Securities [Line Items]
Cash and Cash Equivalents	27.7	9.4
Total	2,742.4	2,528.7
Gross Unrealized Gains	18.2	1.6
Gross Unrealized Losses	0.4	8.6
Fair Value	2,760.2	2,521.7
Short-term Investments	1,163.3	1,307.4
Long-term Investments	1,569.2	1,204.9
Level 2 \| Commercial paper
Schedule of Available-for-sale Securities [Line Items]
Cash and Cash Equivalents	25.5	1.4
Total	165.1	110.7
Gross Unrealized Gains	0.0	0.0
Gross Unrealized Losses	0.0	0.0
Fair Value	165.1	110.7
Short-term Investments	139.6	109.3
Long-term Investments	0.0	0.0
Level 2 \| Corporate securities
Schedule of Available-for-sale Securities [Line Items]
Cash and Cash Equivalents	0.0	8.0
Total	2,096.1	1,607.8
Gross Unrealized Gains	16.8	1.3
Gross Unrealized Losses	0.2	4.8
Fair Value	2,112.7	1,604.3
Short-term Investments	798.5	724.5
Long-term Investments	1,314.2	871.8
Level 2 \| U.S. government agencies
Schedule of Available-for-sale Securities [Line Items]
Cash and Cash Equivalents	0.0	0.0
Total	418.3	791.8
Gross Unrealized Gains	1.1	0.3
Gross Unrealized Losses	0.2	3.8
Fair Value	419.2	788.3
Short-term Investments	209.6	468.9
Long-term Investments	209.6	319.4
Level 2 \| Non-U.S. government securities
Schedule of Available-for-sale Securities [Line Items]
Cash and Cash Equivalents	0.0
Total	4.5
Gross Unrealized Gains	0.0
Gross Unrealized Losses	0.0
Fair Value	4.5
Short-term Investments	4.5
Long-term Investments	0.0
Level 2 \| Municipal securities
Schedule of Available-for-sale Securities [Line Items]
Cash and Cash Equivalents	2.2	0.0
Total	58.4	18.4
Gross Unrealized Gains	0.3	0.0
Gross Unrealized Losses	0.0	0.0
Fair Value	58.7	18.4
Short-term Investments	11.1	4.7
Long-term Investments	$ 45.4	$ 13.7

Commitments and Contingencies - Additional Information (Details) - USD ($) $ in Millions			12 Months Ended
	Dec. 31, 2018	Jun. 11, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Other commitments			$ 845.0
Commitments And Contingencies [Line Items]
Pre-tax settlement charges			0.5	$ 45.2	$ 16.3
Accrued liabilities, product liability claims	$ 53.0		4.2	53.0
Settlement agreement payment		$ 42.5
Pre-tax loss			42.5
Prepaid and other current assets
Commitments And Contingencies [Line Items]
Settlement agreement payment	42.5
da Vinci Surgical System Product Liability Matters
Commitments And Contingencies [Line Items]
Pre-tax settlement charges			0.5	2.7	$ 16.3
Accrued liabilities, product liability claims	$ 10.5		$ 4.2	$ 10.5

Leases - Schedule of Future Minimum Lease Commitments (Details) $ in Millions	Dec. 31, 2018 USD ($)
Leases [Abstract]
2019	$ 15.1
2020	14.5
2021	12.7
2022	11.2
2023	11.0
2024 and thereafter	30.9
Total lease payments	$ 95.4

Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2019

Equity [Abstract]

Schedule Of Stock Repurchase Activities

The following table provides the stock repurchase activities during the years ended December 31, 2019, 2018, and 2017 (in millions, except per share amounts):


	Years Ended December 31,
	2019		2018		2017
Shares repurchased	0.6		—		7.3
Average price per share	$	481.35	$	—	$	310.32
Value of shares repurchased	$	269.5	$	—	$	2,274.0

Components of Accumulated Other Comprehensive Income (Loss), Net of Tax

The components of accumulated other comprehensive income (loss), net of tax, for the years ended December 31, 2019, and 2018, are as follows (in millions):


	Year Ended December 31, 2019
	Gains (Losses) on Hedge Instruments		Unrealized Gains (Losses) on Available-for-Sale Securities		Foreign Currency Translation Gains (Losses)		Employee Benefit Plans		Total
Beginning balance	$	0.2	$	(9.8)	$	(0.3)	$	(3.4)	$	(13.3)
Other comprehensive income (loss) before reclassifications	5.8		30.7		0.3		(5.9)		30.9
Reclassified from accumulated other comprehensive (loss)	(5.3)		(0.5)		—		0.6		(5.2)
Net current-period other comprehensive income (loss)	0.5		30.2		0.3		(5.3)		25.7
Ending balance	$	0.7	$	20.4	$	—	$	(8.7)	$	12.4

	Year Ended December 31, 2018
	Gains (Losses) on Hedge Instruments		Unrealized Gains (Losses) on Available-for-Sale Securities		Foreign Currency Translation Gains (Losses)		Employee Benefit Plans		Total
Beginning balance	$	(2.4)	$	(11.3)	$	2.3	$	(4.1)	$	(15.5)
Other comprehensive income (loss) before reclassifications	3.6		0.3		(2.6)		0.4		1.7
Reclassified from accumulated other comprehensive income (loss)	(1.0)		1.2		—		0.3		0.5
Net current-period other comprehensive income (loss)	2.6		1.5		(2.6)		0.7		2.2
Ending balance	$	0.2	$	(9.8)	$	(0.3)	$	(3.4)	$	(13.3)

Revenue

12 Months Ended

Dec. 31, 2019

Revenue from Contract with Customer [Abstract]

Revenue

REVENUE

The following table presents revenue disaggregated by types and geography (in millions):


	Years Ended December 31,
U.S.	2019		2018		2017
Instruments and accessories	$	1,790.4	$	1,485.2	$	1,263.1
Systems	830.7		692.2		603.5
Services	508.4		456.1		419.2
Total U.S. revenue	$	3,129.5	$	2,633.5	$	2,285.8

Outside of U.S. (“OUS”)
Instruments and accessories	$	617.8	$	476.8	$	373.8
Systems	515.4		434.9		324.9
Services	215.8		179.0		153.7
Total OUS revenue	$	1,349.0	$	1,090.7	$	852.4

Total
Instruments and accessories	$	2,408.2	$	1,962.0	$	1,636.9
Systems	1,346.1		1,127.1		928.4
Services	724.2		635.1		572.9
Total revenue	$	4,478.5	$	3,724.2	$	3,138.2

Remaining Performance Obligations

The transaction price allocated to remaining performance obligations relates to amounts allocated to products and services for which revenue has not yet been recognized. A significant portion of this amount relates to performance obligations in the Company’s service contracts that will be satisfied and recognized as revenue in future periods. In addition, non-lease elements associated with the Company’s lease arrangements are primarily comprised of service contracts that will be satisfied and recognized as revenue in future periods. The transaction price allocated to the remaining performance obligations and the non-lease elements associated with the lease arrangements were $1,597 million as of December 31, 2019. The remaining performance obligations are expected to be satisfied over the term of the individual sales arrangements, which generally are 5 years. Service revenue associated with the lease arrangements will generally be recognized over the service period, which generally coincides with the lease term.

Contract Assets and Liabilities

The following information summarizes the Company’s contract assets and liabilities (in millions):



	As of
	December 31, 2019		December 31, 2018
Contract assets	$	20.8	$	12.4
Deferred revenue	$	365.2	$	327.3

The Company invoices its customers based on the billing schedules in its sales arrangements. Payments are generally due 30 days from date of invoice. Contract assets for the periods presented primarily represent the difference between the revenue that was recognized based on the relative standalone selling price of the related performance obligations satisfied and the contractual billing terms in the arrangements. Deferred revenue for the periods presented primarily relates to service contracts where the service fees are billed up-front, generally quarterly or annually, prior to those services having been performed. The associated deferred revenue is generally recognized over the term of the service period. The Company did not have any significant impairment losses on its contract assets for the periods presented.

During the year ended December 31, 2019, the Company recognized $307 million of revenue that was included in the deferred revenue balance as of December 31, 2018. During the year ended December 31, 2018, the Company recognized $269 million of revenue that was included in the deferred revenue balance as of December 31, 2017.

Intuitive System Leasing

The following table presents revenue from Intuitive System Leasing arrangements (in millions):


	Years Ended December 31,
	2019		2018		2017
Sales-type lease revenue	$	81.6	$	69.8	$	49.5
Operating lease revenue	$	106.9	$	51.4	$	25.9

Consolidated Financial Statement Details - Inventory (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Inventory:
Raw materials	$ 211.0	$ 164.1
Work-in-process	75.9	40.0
Finished goods	308.6	204.9
Total inventory	$ 595.5	$ 409.0

Share-Based Compensation - Outstanding and Exercisable Options Ranges (Details) $ / shares in Units, shares in Millions	12 Months Ended
	Dec. 31, 2019 USD ($) $ / shares shares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Number of Shares \| shares	5.4
Options Outstanding, Weighted Average Remaining Contractual Life	5 years 3 months 18 days
Options Outstanding, Weighted Average Exercise Price Per Share (usd per share)	$ 246.64
Options Outstanding, Aggregate Intrinsic Value \| $	$ 1,844,400,000
Options Exercisable, Number of Shares \| shares	4.3
Options Exercisable, Weighted Average Remaining Contractual Life	4 years 4 months 24 days
Options Exercisable, Weighted Average Exercise Price Per Share (usd per share)	$ 195.76
Options Exercisable, Aggregate Intrinsic Value \| $	$ 1,702,400,000
Closing stock price (usd per share) \| $	$ 591.15
Exercise Price Range 1
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, minimum (usd per share)	$ 86.88
Range of Exercise Prices, maximum (usd per share)	$ 148.03
Options Outstanding, Number of Shares \| shares	1.1
Options Outstanding, Weighted Average Remaining Contractual Life	2 years 9 months 18 days
Options Outstanding, Weighted Average Exercise Price Per Share (usd per share)	$ 127.46
Options Exercisable, Number of Shares \| shares	1.1
Options Exercisable, Weighted Average Exercise Price Per Share (usd per share)	$ 127.46
Exercise Price Range 2
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, minimum (usd per share)	150.50
Range of Exercise Prices, maximum (usd per share)	$ 172.44
Options Outstanding, Number of Shares \| shares	1.4
Options Outstanding, Weighted Average Remaining Contractual Life	3 years 7 months 6 days
Options Outstanding, Weighted Average Exercise Price Per Share (usd per share)	$ 166.28
Options Exercisable, Number of Shares \| shares	1.4
Options Exercisable, Weighted Average Exercise Price Per Share (usd per share)	$ 166.29
Exercise Price Range 3
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, minimum (usd per share)	172.76
Range of Exercise Prices, maximum (usd per share)	$ 231.00
Options Outstanding, Number of Shares \| shares	1.2
Options Outstanding, Weighted Average Remaining Contractual Life	5 years 1 month 6 days
Options Outstanding, Weighted Average Exercise Price Per Share (usd per share)	$ 194.42
Options Exercisable, Number of Shares \| shares	1.2
Options Exercisable, Weighted Average Exercise Price Per Share (usd per share)	$ 193.89
Exercise Price Range 4
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, minimum (usd per share)	231.11
Range of Exercise Prices, maximum (usd per share)	$ 505.36
Options Outstanding, Number of Shares \| shares	1.1
Options Outstanding, Weighted Average Remaining Contractual Life	8 years 1 month 6 days
Options Outstanding, Weighted Average Exercise Price Per Share (usd per share)	$ 376.53
Options Exercisable, Number of Shares \| shares	0.5
Options Exercisable, Weighted Average Exercise Price Per Share (usd per share)	$ 334.67
Exercise Price Range 5
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, minimum (usd per share)	508.19
Range of Exercise Prices, maximum (usd per share)	$ 585.57
Options Outstanding, Number of Shares \| shares	0.6
Options Outstanding, Weighted Average Remaining Contractual Life	9 years
Options Outstanding, Weighted Average Exercise Price Per Share (usd per share)	$ 536.41
Options Exercisable, Number of Shares \| shares	0.1
Options Exercisable, Weighted Average Exercise Price Per Share (usd per share)	$ 531.66

Valuation And Qualifying Accounts (Details) - Allowance for doubtful accounts, loan credit losses, and sales returns - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Year	$ 20.4	$ 14.6	$ 10.8
Additions	46.9	46.0	36.1
Deductions	(45.9)	(40.2)	(32.3)
Balance at End of Year	$ 21.4	$ 20.4	$ 14.6

Stockholders' Equity - Components of Accumulated Other Comprehensive Income, Net of Tax (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	$ 6,678.8
Other comprehensive income (loss) before reclassifications	30.9	$ 1.7
Reclassified from accumulated other comprehensive (loss)	(5.2)	0.5
Other comprehensive gains (losses)	25.7	2.2	$ (6.6)
Ending balance	8,263.8	6,678.8
Gains (Losses) on Hedge Instruments
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	0.2	(2.4)
Other comprehensive income (loss) before reclassifications	5.8	3.6
Reclassified from accumulated other comprehensive (loss)	(5.3)	(1.0)
Other comprehensive gains (losses)	0.5	2.6
Ending balance	0.7	0.2	(2.4)
Unrealized Gains (Losses) on Available-for-Sale Securities
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(9.8)	(11.3)
Other comprehensive income (loss) before reclassifications	30.7	0.3
Reclassified from accumulated other comprehensive (loss)	(0.5)	1.2
Other comprehensive gains (losses)	30.2	1.5
Ending balance	20.4	(9.8)	(11.3)
Foreign Currency Translation Gains (Losses)
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(0.3)	2.3
Other comprehensive income (loss) before reclassifications	0.3	(2.6)
Reclassified from accumulated other comprehensive (loss)	0.0	0.0
Other comprehensive gains (losses)	0.3	(2.6)
Ending balance	0.0	(0.3)	2.3
Employee Benefit Plans
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(3.4)	(4.1)
Other comprehensive income (loss) before reclassifications	(5.9)	0.4
Reclassified from accumulated other comprehensive (loss)	0.6	0.3
Other comprehensive gains (losses)	(5.3)	0.7
Ending balance	(8.7)	(3.4)	(4.1)
Total
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(13.3)	(15.5)
Ending balance	$ 12.4	$ (13.3)	$ (15.5)